Interferon	O
affects	O
nuclear	B-protein
proteins	I-protein
in	O
cells	O
of	O
clinically	O
sensitive	O
chronic	O
myelogenous	O
leukemia	O
patients	O
.	O

Cytoplasmic	O
protein	O
extracts	O
from	O
chronic	B-cell_type
myelogenous	I-cell_type
leukemia	I-cell_type
(	I-cell_type
CML	I-cell_type
)	I-cell_type
cells	I-cell_type
contained	O
an	O
activity	O
that	O
altered	O
the	O
electrophoretic	O
mobility	O
of	O
complexes	O
formed	O
between	O
nuclear	B-protein
proteins	I-protein
and	O
the	O
transcriptional	O
enhancers	O
of	O
interferon	O
(	O
IFN	O
)	O
-inducible	O
genes	O
.	O

Exposure	O
of	O
CML	B-cell_type
cells	I-cell_type
to	O
IFN-alpha	B-protein
diminished	O
the	O
effect	O
of	O
the	O
CML	B-protein
cytoplasmic	I-protein
proteins	I-protein
on	O
these	O
nuclear	B-protein
protein-DNA	I-protein
complexes	I-protein
.	O

The	O
presence	O
of	O
clinical	O
responsiveness	O
to	O
IFN-alpha	B-protein
correlated	O
with	O
the	O
sensitivity	O
to	O
the	O
IFN	B-protein
-induced	O
change	O
in	O
the	O
electrophoretic	O
mobility	O
of	O
nuclear	B-protein
protein-DNA	I-protein
complexes	I-protein
.	O

These	O
data	O
suggest	O
that	O
the	O
action	O
of	O
IFN-alpha	B-protein
in	O
CML	O
may	O
be	O
linked	O
to	O
a	O
pathway	O
that	O
can	O
result	O
in	O
posttranslational	O
modification	O
of	O
nuclear	B-protein
proteins	I-protein
.	O

From	NULL
www	NULL
.	NULL

bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

Interferon	NULL
Affects	NULL
Nuclear	NULL
Proteins	NULL
in	NULL
Cells	NULL
of	NULL
Clinically	NULL
Sensitive	NULL
Chronic	NULL
Myelogenous	NULL
Leukemia	NULL
Patients	NULL
By	NULL
O.M	NULL
.	NULL

Zack	NULL
Howard	NULL
,	NULL
Moshe	NULL
Talpaz	NULL
,	NULL
Hagop	NULL
Kantarfjian	NULL
,	NULL
David	NULL
Seong	NULL
,	NULL
Andrzej	NULL
Wedrychowski	NULL
,	NULL
Nikolaos	NULL
Paslidis	NULL
,	NULL
Jeane	NULL
Hester	NULL
,	NULL
Anne	NULL
Cork	NULL
,	NULL
James	NULL
Turpin	NULL
,	NULL
Gabriel	NULL
Lopez-Berestein	NULL
,	NULL
Jose	NULL
Trujillo	NULL
,	NULL
Jordan	NULL
Gutterman	NULL
,	NULL
Emil	NULL
Freireich	NULL
,	NULL
and	NULL
Albert	NULL
Deisseroth	NULL
Cytoplasmic	NULL
protein	NULL
extracts	NULL
from	NULL
chronic	NULL
myelogenous	NULL
leukemia	NULL
(	NULL
CML	NULL
)	NULL
cells	NULL
contained	NULL
an	NULL
activity	NULL
that	NULL
altered	NULL
the	NULL
electrophoretic	NULL
mobility	NULL
of	NULL
complexes	NULL
formed	NULL
between	NULL
nuclear	NULL
proteins	NULL
and	NULL
the	NULL
transcriptional	NULL
enhancers	NULL
of	NULL
interferon	NULL
(	NULL
IFN	NULL
)	NULL
-inducible	NULL
genes	NULL
.	NULL

Exposure	NULL
of	NULL
CML	NULL
cells	NULL
to	NULL
IFN-	NULL
«	NULL
diminished	NULL
the	NULL
effect	NULL
of	NULL
the	NULL
CML	NULL
cytoplasmic	NULL
proteins	NULL
on	NULL
these	NULL
nuclear	NULL
protein-DNA	NULL
complexes	NULL
.	NULL

The	NULL
pres	NULL
N	NULL
CHRONIC	NULL
myelogenous	NULL
leukemia	NULL
(	NULL
CML	NULL
)	NULL
,	NULL
an	NULL
underlying	NULL
defect	NULL
in	NULL
growth	NULL
regulation	NULL
related	NULL
to	NULL
the	NULL
Philadelphia	NULL
chromosome	NULL
translocation	NULL
leads	NULL
to	NULL
an	NULL
accumulation	NULL
of	NULL
high	NULL
numbers	NULL
of	NULL
myeloid	NULL
cells	NULL
.	NULL

The	NULL
chronic	NULL
or	NULL
benign	NULL
phase	NULL
lasts	NULL
a	NULL
median	NULL
of	NULL
4	NULL
years	NULL
,	NULL
following	NULL
which	NULL
the	NULL
acquisition	NULL
of	NULL
additional	NULL
mutations	NULL
leads	NULL
to	NULL
a	NULL
more	NULL
acute	NULL
form	NULL
of	NULL
leukemia	NULL
in	NULL
which	NULL
the	NULL
patients	NULL
die	NULL
of	NULL
bleeding	NULL
and	NULL
infection	NULL
.	NULL

!	NULL

Alpha-interferon	NULL
(	NULL
IFN-a	NULL
@	NULL
)	NULL
induces	NULL
complete	NULL
hematologic	NULL
remissions	NULL
(	NULL
all	NULL
cells	NULL
are	NULL
Philadelphia	NULL
chromosome-positive	NULL
,	NULL
but	NULL
the	NULL
differential	NULL
count	NULL
and	NULL
white	NULL
blood	NULL
cell	NULL
count	NULL
are	NULL
normal	NULL
)	NULL
in	NULL
70	NULL
%	NULL
of	NULL
patients	NULL
and	NULL
a	NULL
complete	NULL
cytogenetic	NULL
remission	NULL
(	NULL
all	NULL
cells	NULL
are	NULL
diploid	NULL
)	NULL
in	NULL
15	NULL
%	NULL
of	NULL
early	NULL
phase	NULL
CML	NULL
patients	NULL
.	NULL
'	NULL

Fifteen	NULL
percent	NULL
to	NULL
30	NULL
%	NULL
of	NULL
early	NULL
chronic	NULL
phase	NULL
CML	NULL
patients	NULL
show	NULL
primary	NULL
resistance	NULL
to	NULL
IFN-a	NULL
at	NULL
diagno-sis	NULL
.	NULL

The	NULL
mechanism	NULL
through	NULL
which	NULL
IFN-	NULL
«	NULL
#	NULL
mediates	NULL
its	NULL
clinical	NULL
effect	NULL
in	NULL
CML	NULL
and	NULL
the	NULL
reasons	NULL
for	NULL
these	NULL
variable	NULL
levels	NULL
of	NULL
sensitivity	NULL
to	NULL
IFN	NULL
are	NULL
unknown	NULL
.	NULL

Alpha-interferon	NULL
exerts	NULL
its	NULL
immunomodulatory	NULL
and	NULL
antiviral	NULL
effects	NULL
by	NULL
activating	NULL
the	NULL
transcription	NULL
of	NULL
histocompatibility	NULL
and	NULL
antiviral	NULL
genes	NULL
.	NULL

It	NULL
also	NULL
alters	NULL
the	NULL
transcriptional	NULL
activity	NULL
of	NULL
several	NULL
other	NULL
genes	NULL
commonly	NULL
known	NULL
as	NULL
IFN-inducible	NULL
genes	NULL
.	NULL

This	NULL
transcriptional	NULL
activation	NULL
is	NULL
mediated	NULL
through	NULL
alteration	NULL
of	NULL
nuclear	NULL
proteins	NULL
that	NULL
bind	NULL
to	NULL
the	NULL
5	NULL
'	NULL
transcription-regulatory	NULL
regions	NULL
of	NULL
IFN-inducible	NULL
genes	NULL
before	NULL
the	NULL
activation	NULL
of	NULL
gene	NULL
expression	NULL
.	NULL

**	NULL
To	NULL
test	NULL
the	NULL
hypothesis	NULL
that	NULL
the	NULL
action	NULL
of	NULL
IFN-a	NULL
in	NULL
CML	NULL
is	NULL
also	NULL
associated	NULL
with	NULL
changes	NULL
in	NULL
nuclear	NULL
DNA-binding	NULL
proteins	NULL
,	NULL
we	NULL
isolated	NULL
nuclear	NULL
proteins	NULL
from	NULL
CML	NULL
patients	NULL
who	NULL
were	NULL
either	NULL
clinically	NULL
resistant	NULL
or	NULL
sensitive	NULL
to	NULL
IFN-	NULL
.	NULL

We	NULL
then	NULL
studied	NULL
the	NULL
electrophoretic	NULL
mobility	NULL
of	NULL
the	NULL
complexes	NULL
formed	NULL
between	NULL
these	NULL
nuclear	NULL
proteins	NULL
and	NULL
IFN-inducible	NULL
transcriptional	NULL
enhancers	NULL
.	NULL

The	NULL
transcriptional	NULL
enhancers	NULL
used	NULL
were	NULL
taken	NULL
from	NULL
the	NULL
5	NULL
'	NULL
region	NULL
of	NULL
the	NULL
IFN	NULL
antiviral	NULL
gene	NULL
2,5-oligoadenylate	NULL
synthetase	NULL
(	NULL
2,5-0AS8	NULL
)	NULL
,	NULL
*	NULL
``	NULL
the	NULL
IFN	NULL
immunomodulatory	NULL
gene	NULL
beta-2	NULL
microglobulin	NULL
,	NULL
'	NULL
and	NULL
the	NULL
IFN-inducible	NULL
genes	NULL
9-27	NULL
``	NULL
and	NULL
6-16	NULL
,	NULL
°	NULL
which	NULL
are	NULL
of	NULL
unknown	NULL
function	NULL
.	NULL
``	NULL

We	NULL
found	NULL
that	NULL
the	NULL
electrophoretic	NULL
mobility	NULL
of	NULL
complexes	NULL
between	NULL
the	NULL
IFN-inducible	NULL
transcriptional	NULL
enhancers	NULL
and	NULL
the	NULL
nuclear	NULL
proteins	NULL
isolated	NULL
from	NULL
the	NULL
unfractionated	NULL
peripheral	NULL
blood	NULL
cells	NULL
of	NULL
CML	NULL
and	NULL
normal	NULL
individuals	NULL
were	NULL
different	NULL
before	NULL
IFN	NULL
exposure	NULL
.	NULL

The	NULL
complexes	NULL
formed	NULL
by	NULL
nuclear	NULL
proteins	NULL
isolated	NULL
from	NULL
unfractionated	NULL
normal	NULL
peripheral	NULL
blood	NULL
cells	NULL
resembled	NULL
those	NULL
formed	NULL
by	NULL
nuclear	NULL
proteins	NULL
from	NULL
unfractionated	NULL
CML	NULL
peripheral	NULL
blood	NULL
cells	NULL
after	NULL
the	NULL
Blood	NULL
,	NULL
Vol	NULL
76	NULL
,	NULL
No	NULL
6	NULL
(	NULL
September	NULL
15	NULL
)	NULL
,	NULL
1990	NULL
:	NULL
pp	NULL
1117-1130	NULL
ence	NULL
of	NULL
clinical	NULL
responsiveness	NULL
to	NULL
IFN-	NULL
«	NULL
correlated	NULL
with	NULL
the	NULL
sensitivity	NULL
to	NULL
the	NULL
IFN-induced	NULL
change	NULL
in	NULL
the	NULL
electrophoretic	NULL
mobility	NULL
of	NULL
nuclear	NULL
protein-DNA	NULL
complexes	NULL
.	NULL

These	NULL
data	NULL
suggest	NULL
that	NULL
the	NULL
action	NULL
of	NULL
IFN-a	NULL
in	NULL
CML	NULL
may	NULL
be	NULL
linked	NULL
to	NULL
a	NULL
pathway	NULL
that	NULL
can	NULL
result	NULL
in	NULL
posttranslational	NULL
modification	NULL
of	NULL
nuclear	NULL
proteins	NULL
.	NULL

©	NULL
1990	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
.	NULL

nuclear	NULL
proteins	NULL
from	NULL
normal	NULL
peripheral	NULL
blood	NULL
cells	NULL
were	NULL
exposed	NULL
to	NULL
a	NULL
phosphatase-like	NULL
activity	NULL
found	NULL
in	NULL
cytoplasmic	NULL
proteins	NULL
of	NULL
CML	NULL
myeloid	NULL
cells	NULL
.	NULL

Alpha-interferon	NULL
treatment	NULL
changed	NULL
the	NULL
electrophoretic	NULL
mobility	NULL
pattern	NULL
of	NULL
complexes	NULL
formed	NULL
by	NULL
nuclear	NULL
proteins	NULL
of	NULL
CML	NULL
peripheral	NULL
blood	NULL
to	NULL
that	NULL
of	NULL
normal	NULL
peripheral	NULL
blood	NULL
cells	NULL
.	NULL

This	NULL
IFN-induced	NULL
change	NULL
occurred	NULL
in	NULL
CML	NULL
patients	NULL
who	NULL
were	NULL
known	NULL
to	NULL
be	NULL
clinically	NULL
sensitive	NULL
to	NULL
IFN-a	NULL
but	NULL
did	NULL
not	NULL
occur	NULL
in	NULL
CML	NULL
patients	NULL
who	NULL
were	NULL
clinically	NULL
resistant	NULL
to	NULL
IFN-a	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
In	NULL
vitro	NULL
and	NULL
in	NULL
vivo	NULL
use	NULL
of	NULL
alpha-interferon	NULL
.	NULL

Patients	NULL
were	NULL
treated	NULL
with	NULL
daily	NULL
subcutaneous	NULL
injections	NULL
of	NULL
5	NULL
to	NULL
10	NULL
x	NULL
10°	NULL
U	NULL
of	NULL
IFN-a	NULL
.	NULL

In	NULL
vitro	NULL
experiments	NULL
involved	NULL
the	NULL
use	NULL
of	NULL
1,000	NULL
U/mL	NULL
of	NULL
recombinant	NULL
IFN-a	NULL
at	NULL
37°C	NULL
at	NULL
pH	NULL
7.4	NULL
for	NULL
1	NULL
hour	NULL
.	NULL

The	NULL
concentration	NULL
used	NULL
for	NULL
in	NULL
vitro	NULL
experiments	NULL
(	NULL
1,000	NULL
U/mL	NULL
)	NULL
is	NULL
four	NULL
times	NULL
the	NULL
peak	NULL
serum	NULL
level	NULL
usually	NULL
seen	NULL
2	NULL
hours	NULL
after	NULL
a	NULL
subcutaneous	NULL
injection	NULL
of	NULL
5	NULL
x	NULL
10°	NULL
U	NULL
of	NULL
recombinant	NULL
IFN-a	NULL
.	NULL

The	NULL
peripheral	NULL
blood	NULL
samples	NULL
used	NULL
for	NULL
this	NULL
study	NULL
were	NULL
obtained	NULL
as	NULL
incidental	NULL
samples	NULL
from	NULL
routine	NULL
diagnostic	NULL
or	NULL
response	NULL
evaluation	NULL
procedures	NULL
approved	NULL
by	NULL
the	NULL
M.D	NULL
.	NULL

Anderson	NULL
Surveillance	NULL
Commit-tee	NULL
.	NULL

Some	NULL
of	NULL
the	NULL
samples	NULL
from	NULL
CML	NULL
patients	NULL
``	NULL
off	NULL
of	NULL
IFN	NULL
``	NULL
(	NULL
patient	NULL
not	NULL
receiving	NULL
IFN	NULL
at	NULL
time	NULL
sample	NULL
was	NULL
taken	NULL
)	NULL
were	NULL
obtained	NULL
at	NULL
diagnosis	NULL
before	NULL
institution	NULL
of	NULL
therapy	NULL
,	NULL
while	NULL
all	NULL
of	NULL
the	NULL
samples	NULL
from	NULL
CML	NULL
patients	NULL
receiving	NULL
IFN	NULL
were	NULL
obtained	NULL
at	NULL
variable	NULL
time	NULL
points	NULL
after	NULL
initiation	NULL
of	NULL
IFN	NULL
therapy	NULL
.	NULL

The	NULL
time	NULL
after	NULL
initiation	NULL
of	NULL
therapy	NULL
at	NULL
which	NULL
these	NULL
samples	NULL
were	NULL
obtained	NULL
is	NULL
indicated	NULL
in	NULL
Table	NULL
4	NULL
(	NULL
see	NULL
Results	NULL
)	NULL
.	NULL

This	NULL
is	NULL
primarily	NULL
a	NULL
retrospective	NULL
study	NULL
in	NULL
that	NULL
the	NULL
majority	NULL
of	NULL
samples	NULL
were	NULL
obtained	NULL
after	NULL
the	NULL
response	NULL
status	NULL
was	NULL
known	NULL
.	NULL

From	NULL
the	NULL
Departments	NULL
of	NULL
Hematology	NULL
and	NULL
Clinical	NULL
Immunology	NULL
and	NULL
Biological	NULL
Therapy	NULL
,	NULL
and	NULL
Division	NULL
of	NULL
Laboratory	NULL
Medicine	NULL
,	NULL
The	NULL
University	NULL
of	NULL
Texas	NULL
M.D	NULL
.	NULL

Anderson	NULL
Cancer	NULL
Center	NULL
,	NULL
Houston	NULL
,	NULL
TX	NULL
.	NULL

Submitted	NULL
November	NULL
15	NULL
,	NULL
1989	NULL
;	NULL
accepted	NULL
May	NULL
18	NULL
,	NULL
1990	NULL
.	NULL

Supported	NULL
by	NULL
grants	NULL
to	NULL
A.D.	NULL
from	NULL
the	NULL
Kleberg	NULL
Foundation	NULL
,	NULL
the	NULL
Gillson-Longenbaugh	NULL
Foundation	NULL
,	NULL
the	NULL
Sid	NULL
Richardson	NULL
Foundation	NULL
,	NULL
The	NULL
American	NULL
Cancer	NULL
Society	NULL
,	NULL
and	NULL
the	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
(	NULL
POI	NULL
CA49639-01	NULL
A1	NULL
)	NULL
,	NULL
and	NULL
a	NULL
scholar	NULL
grant	NULL
from	NULL
the	NULL
Leukemia	NULL
Society	NULL
of	NULL
America	NULL
to	NULL
G.L-B	NULL
.	NULL

Address	NULL
reprint	NULL
requests	NULL
to	NULL
Albert	NULL
Deisseroth	NULL
,	NULL
MD	NULL
,	NULL
PhD	NULL
,	NULL
Department	NULL
of	NULL
Hematology	NULL
,	NULL
Box	NULL
24	NULL
,	NULL
M.D	NULL
.	NULL

Anderson	NULL
Cancer	NULL
Center	NULL
,	NULL
1515	NULL
Holcombe	NULL
Blvd	NULL
,	NULL
Houston	NULL
,	NULL
TX	NULL
77030	NULL
.	NULL

The	NULL
publication	NULL
costs	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
page	NULL
charge	NULL
payment	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
advertisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

©	NULL
1990	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
.	NULL

0006-497	NULL
1/90/7606-0008	NULL
$	NULL
3.00/0	NULL
1117	NULL
From	NULL
www	NULL
.	NULL

bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

1118	NULL
HOWARD	NULL
ET	NULL
AL	NULL
H	NULL
-a	NULL
l	NULL
«	NULL
-	NULL
B	NULL
1	NULL
2	NULL
b	NULL
C	NULL
a	NULL
1	NULL
2	NULL
Fig	NULL
1	NULL
.	NULL

(	NULL
a	NULL
)	NULL
Complexes	NULL
formed	NULL
by	NULL
nuclear	NULL
proteins	NULL
of	NULL
purified	NULL
normal	NULL
lymphocytes	NULL
and	NULL
monocytes	NULL
.	NULL

The	NULL
interferon-inducible	NULL
transcriptional	NULL
enhancer	NULL
of	NULL
the	NULL
2,5-0AS	NULL
gene	NULL
and	NULL
the	NULL
nuclear	NULL
proteins	NULL
isolated	NULL
from	NULL
purified	NULL
normal	NULL
monocytes	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
form	NULL
a	NULL
high-mobility	NULL
complex	NULL
(	NULL
band	NULL
B	NULL
)	NULL
.	NULL

The	NULL
nuclear	NULL
proteins	NULL
isolated	NULL
from	NULL
purified	NULL
normal	NULL
lymphocytes	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
form	NULL
a	NULL
low-mobility	NULL
complex	NULL
(	NULL
band	NULL
A	NULL
)	NULL
.	NULL

Lymphocytes	NULL
and	NULL
monocytes	NULL
were	NULL
isolated	NULL
first	NULL
from	NULL
peripheral	NULL
blood	NULL
by	NULL
continuous	NULL
flow	NULL
centrifugation	NULL
.	NULL

Lymphocytes	NULL
or	NULL
monocytes	NULL
were	NULL
then	NULL
isolated	NULL
from	NULL
the	NULL
continuous-flow	NULL
centrifugation	NULL
fraction	NULL
by	NULL
elutriation	NULL
.	NULL

The	NULL
purity	NULL
of	NULL
these	NULL
fractions	NULL
for	NULL
lymphocytes	NULL
or	NULL
ytes	NULL
was	NULL
d	NULL
by	NULL
histochemical	NULL
stains	NULL
.	NULL

This	NULL
gel	NULL
was	NULL
run	NULL
for	NULL
12	NULL
hours	NULL
at	NULL
5	NULL
V/cm	NULL
.	NULL

The	NULL
area	NULL
at	NULL
the	NULL
bottom	NULL
of	NULL
the	NULL
lane	NULL
shows	NULL
the	NULL
unbound	NULL
probe	NULL
.	NULL

(	NULL
bDWngMWmembd-todﬁommmmw	NULL
Complexes	NULL
formed	NULL
between	NULL
the	NULL
2,5-0AS	NULL
transcriptional	NULL
and	NULL
proteins	NULL
of	NULL
the	NULL
EM-2	NULL
(	NULL
myeloid	NULL
phenotype	NULL
)	NULL
CML	NULL
cell	NULL
line	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
and	NULL
the	NULL
SP-5	NULL
(	NULL
lymphoid	NULL
phenotype	NULL
)	NULL
T-cell	NULL
lymphatic	NULL
leukemia	NULL
cell	NULL
line	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
.	NULL

The	NULL
low-mobility	NULL
complex	NULL
is	NULL
band	NULL
A	NULL
and	NULL
the	NULL
high-mobility	NULL
complex	NULL
is	NULL
band	NULL
B	NULL
.	NULL

The	NULL
gel	NULL
was	NULL
run	NULL
at	NULL
5	NULL
V	NULL
/cm	NULL
for	NULL
12	NULL
hours	NULL
.	NULL

The	NULL
area	NULL
at	NULL
the	NULL
bottom	NULL
of	NULL
the	NULL
lane	NULL
shows	NULL
the	NULL
free	NULL
probe	NULL
.	NULL

(	NULL
c	NULL
)	NULL
Complexes	NULL
between	NULL
nuclear	NULL
proteins	NULL
of	NULL
lymphoid	NULL
and	NULL
myeloid	NULL
cell	NULL
lines	NULL
and	NULL
the	NULL
IFN-inducible	NULL
transcriptional	NULL
enhancers	NULL
of	NULL
the	NULL
6-16	NULL
,	NULL
9-27	NULL
,	NULL
beta-2	NULL
microglobulin	NULL
,	NULL
and	NULL
2,5-OAS	NULL
genes	NULL
.	NULL

The	NULL
nuclear	NULL
proteins	NULL
of	NULL
the	NULL
SP-5	NULL
lymphoid	NULL
cell	NULL
line	NULL
(	NULL
lanes	NULL
1	NULL
,	NULL
3	NULL
,	NULL
5	NULL
,	NULL
and	NULL
7	NULL
)	NULL
or	NULL
the	NULL
EM-2	NULL
myeloid	NULL
cell	NULL
line	NULL
(	NULL
Ianes	NULL
2	NULL
,	NULL
4	NULL
,	NULL
6	NULL
,	NULL
and	NULL
8	NULL
)	NULL
were	NULL
incubated	NULL
with	NULL
the	NULL
transcriptional	NULL
enhancers	NULL
of	NULL
the	NULL
2,5-O0AS	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
,	NULL
beta-2	NULL
microglobulin	NULL
(	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
)	NULL
,	NULL
6-16	NULL
(	NULL
lanes	NULL
5	NULL
and	NULL
6	NULL
)	NULL
,	NULL
and	NULL
9-27	NULL
(	NULL
lanes	NULL
7	NULL
and	NULL
8	NULL
)	NULL
genes	NULL
.	NULL

The	NULL
sequences	NULL
of	NULL
these	NULL
transcriptional	NULL
enhancers	NULL
are	NULL
outlined	NULL
in	NULL
Table	NULL
1	NULL
.	NULL

The	NULL
nuclear	NULL
protein-DNA	NULL
complexes	NULL
were	NULL
electrophoresed	NULL
in	NULL
a	NULL
7	NULL
%	NULL
polyacrylamide	NULL
nondenaturing	NULL
gel	NULL
at	NULL
low	NULL
ionic	NULL
strength	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

The	NULL
gel	NULL
was	NULL
run	NULL
for	NULL
12	NULL
hours	NULL
at	NULL
5	NULL
V	NULL
/cm	NULL
.	NULL

The	NULL
low-mobility	NULL
complex	NULL
is	NULL
band	NULL
A	NULL
and	NULL
the	NULL
high-mobility	NULL
complex	NULL
is	NULL
band	NULL
B	NULL
.	NULL

The	NULL
area	NULL
at	NULL
the	NULL
bottom	NULL
of	NULL
the	NULL
lane	NULL
shows	NULL
the	NULL
free	NULL
probe	NULL
.	NULL

Table	NULL
1	NULL
.	NULL

Interferon-inducible	NULL
Transcriptional	NULL
Enhancer	NULL
5°	NULL
to	NULL
Interferon-inducible	NULL
Genes	NULL
Position	NULL
5°	NULL
to	NULL
Translation	NULL
Start	NULL
Gene	NULL
Sequence	NULL
Codon	NULL
(	NULL
ATG	NULL
)	NULL
of	NULL
Gene	NULL
References	NULL
2,5-0AS	NULL
AGCTCCTCCCTTCTGAGGAAACGAAACCAACAGCAGTCCAA	NULL
-1§5	NULL
8	NULL
Beta-2	NULL
microglobulin	NULL
AGACTCTAAGAAAAGGAAACTGAAAACGGAAAGTCCCTCTCTCTA	NULL
-	NULL
138	NULL
4	NULL
9-27	NULL
ATTTACAAACAGCAGGAAATAGAAACTTAAGAGAAATACACACT	NULL
-	NULL
143	NULL
7	NULL
6-16	NULL
GAGCTGGGAGAGAGGGAAAATGAAACTGCAGAGTGCAGAAATA-	NULL
-88	NULL
5	NULL
GAAACTGCAGAGTGCAG	NULL
From	NULL
www	NULL
.	NULL

bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

INTERFERON	NULL
AND	NULL
NUCLEAR	NULL
PROTEINS	NULL
IN	NULL
CML	NULL
1119	NULL
Fig	NULL
2	NULL
.	NULL

Sequence	NULL
specificity	NULL
of	NULL
nuclear	NULL
protein	NULL
binding	NULL
assay	NULL
.	NULL

A	NULL
P-labeled	NULL
oligonucleotide	NULL
containing	NULL
the	NULL
IFN-a	NULL
regulatory	NULL
site	NULL
of	NULL
the	NULL
2,5-0AS	NULL
gene	NULL
was	NULL
added	NULL
to	NULL
nuclear	NULL
proteins	NULL
of	NULL
the	NULL
HL6O	NULL
cell	NULL
line	NULL
(	NULL
HL6O	NULL
was	NULL
chosen	NULL
because	NULL
its	NULL
nuclear	NULL
proteins	NULL
form	NULL
both	NULL
the	NULL
high-	NULL
and	NULL
low-mobility	NULL
complexes	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
0.1	NULL
ug/	NULL
ul	NULL
.	NULL

of	NULL
poly	NULL
(	NULL
di	NULL
)	NULL
poly	NULL
(	NULL
dC	NULL
)	NULL
and	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
a	NULL
50-fold	NULL
(	NULL
lanes	NULL
1	NULL
,	NULL
3	NULL
,	NULL
5	NULL
,	NULL
7	NULL
,	NULL
9	NULL
,	NULL
11	NULL
,	NULL
13	NULL
,	NULL
15	NULL
,	NULL
17	NULL
,	NULL
and	NULL
19	NULL
)	NULL
or	NULL
100-fold	NULL
(	NULL
lanes	NULL
2	NULL
,	NULL
4	NULL
,	NULL
6	NULL
,	NULL
8	NULL
,	NULL
10	NULL
,	NULL
12	NULL
,	NULL
14	NULL
,	NULL
16	NULL
,	NULL
1a..mzo	NULL
)	NULL
oxuuammmmmmmmmm	NULL
SP-1	NULL
binding	NULL
site	NULL
(	NULL
GGGGCGGGGCGGGGCGGGG	NULL
)	NULL
,	NULL
which	NULL
ins	NULL
no	NULL
h	NULL
and	NULL
does	NULL
not	NULL
compete	NULL
the	NULL
labeled	NULL
oligonucleotide	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
;	NULL
5	NULL
'	NULL
regulatory	NULL
region	NULL
of	NULL
the	NULL
bacterial	NULL
alkaline	NULL
phosphatase	NULL
gene	NULL
(	NULL
GAGACTTATAGTCGCTT	NULL
}	NULL
,	NULL
which	NULL
is	NULL
not	NULL
homologous	NULL
and	NULL
does	NULL
not	NULL
compete	NULL
(	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
)	NULL
;	NULL
a	NULL
5	NULL
'	NULL
regulatory	NULL
site	NULL
of	NULL
the	NULL
zeta	NULL
globin	NULL
gene	NULL
(	NULL
TGTGGTCAGACTCTGGCCAACACCCCCTGTAAGGCCACA	NULL
,	NULL
which	NULL
is	NULL
-	NULL
178	NULL
nucleotides	NULL
5	NULL
to	NULL
the	NULL
zeta	NULL
globin	NULL
CAP	NULL
site	NULL
,	NULL
the	NULL
underlined	NULL
region	NULL
of	NULL
which	NULL
is	NULL
homologous	NULL
ts	NULL
the	NULL
3	NULL
``	NULL
end	NULL
of	NULL
the	NULL
2,5-0AS	NULL
site	NULL
(	NULL
TGTGCTCA	NULL
)	NULL
and	NULL
which	NULL
does	NULL
compete	NULL
(	NULL
lanes	NULL
5	NULL
and	NULL
6	NULL
)	NULL
;	NULL
a	NULL
region	NULL
-	NULL
87	NULL
nucleotides	NULL
5°	NULL
to	NULL
the	NULL
CAP	NULL
site	NULL
of	NULL
the	NULL
zeta	NULL
globin	NULL
gene	NULL
(	NULL
TCTGATAAGAAACACCACCCCTG	NULL
}	NULL
,	NULL
which	NULL
is	NULL
not	NULL
homologous	NULL
to	NULL
the	NULL
2,5-0AS	NULL
site	NULL
and	NULL
does	NULL
not	NULL
compete	NULL
(	NULL
lanes	NULL
7	NULL
and	NULL
8	NULL
)	NULL
;	NULL
a	NULL
region	NULL
-	NULL
65	NULL
nucleotides	NULL
5	NULL
'	NULL
to	NULL
the	NULL
CAP	NULL
site	NULL
of	NULL
the	NULL
zeta	NULL
globin	NULL
gene	NULL
(	NULL
CAGCCCCCTCCCCTCACCTGA	NULL
}	NULL
,	NULL
which	NULL
is	NULL
not	NULL
and	NULL
does	NULL
not	NULL
compete	NULL
(	NULL
lanes	NULL
9	NULL
and	NULL
10	NULL
)	NULL
;	NULL
a	NULL
region	NULL
-	NULL
0	NULL
to	NULL
-	NULL
23	NULL
nucleotides	NULL
5	NULL
'	NULL
to	NULL
the	NULL
CAP	NULL
site	NULL
of	NULL
the	NULL
zeta	NULL
globin	NULL
gene	NULL
(	NULL
GGGGACCCTGGGGGCTGAGCACT	NULL
}	NULL
,	NULL
which	NULL
is	NULL
not	NULL
homologous	NULL
and	NULL
does	NULL
not	NULL
compete	NULL
(	NULL
lanes	NULL
11	NULL
and	NULL
12	NULL
)	NULL
;	NULL
the	NULL
5¢	NULL
region	NULL
of	NULL
the	NULL
granulocyte-macrophage-colony-stimulating	NULL
factor	NULL
gene	NULL
regulatory	NULL
region	NULL
(	NULL
TTCCCTGGCATTTTGTGCTCACCA	NULL
}	NULL
,	NULL
the	NULL
underlined	NULL
region	NULL
of	NULL
which	NULL
is	NULL
homologous	NULL
to	NULL
the	NULL
3°	NULL
end	NULL
(	NULL
TGTGCTCA	NULL
)	NULL
of	NULL
the	NULL
2,5-0AS	NULL
transcriptional	NULL
enhancer	NULL
and	NULL
does	NULL
compete	NULL
(	NULL
lanes	NULL
13	NULL
and	NULL
14	NULL
)	NULL
;	NULL
the	NULL
5¢	NULL
regulatory	NULL
region	NULL
of	NULL
the	NULL
interleukin-3	NULL
gene	NULL
(	NULL
GCCTTGC-CCGGGGT	NULL
TGTGGGCACCT	NULL
}	NULL
,	NULL
the	NULL
underlined	NULL
region	NULL
of	NULL
which	NULL
is	NULL
homologous	NULL
to	NULL
the	NULL
3	NULL
'	NULL
end	NULL
(	NULL
TGTGCTGTGCA	NULL
)	NULL
of	NULL
the	NULL
2,5-0AS	NULL
transcriptional	NULL
enhancer	NULL
and	NULL
does	NULL
compete	NULL
(	NULL
lanes	NULL
15	NULL
and	NULL
16	NULL
)	NULL
;	NULL
the	NULL
2,5-0AS	NULL
regulatory	NULL
transcriptional	NULL
enhancer	NULL
itself	NULL
,	NULL
which	NULL
does	NULL
compete	NULL
(	NULL
lanes	NULL
17	NULL
and	NULL
18	NULL
)	NULL
;	NULL
a	NULL
region	NULL
-	NULL
117	NULL
nucleotides	NULL
5	NULL
'	NULL
to	NULL
the	NULL
translation	NULL
site	NULL
of	NULL
the	NULL
2,5-0AS	NULL
gene	NULL
(	NULL
GCAAAAGGAAAGTGCAAAGA	NULL
}	NULL
,	NULL
the	NULL
underlined	NULL
region	NULL
of	NULL
which	NULL
is	NULL
homologous	NULL
to	NULL
the	NULL
underlined	NULL
region	NULL
TCCTCCCTTCTGAGGAAACGAAACCAACAGCAGTCCAA	NULL
of	NULL
the	NULL
2,5-0AS	NULL
interferon	NULL
regulatory	NULL
site	NULL
(	NULL
excluding	NULL
an	NULL
extra	NULL
TG	NULL
in	NULL
the	NULL
5°	NULL
2,5-0AS	NULL
site	NULL
)	NULL
and	NULL
does	NULL
compete	NULL
(	NULL
lanes	NULL
19	NULL
and	NULL
20	NULL
)	NULL
;	NULL
and	NULL
lane	NULL
21	NULL
,	NULL
which	NULL
contains	NULL
the	NULL
2,5-0AS	NULL
end-labeled	NULL
site	NULL
and	NULL
K562	NULL
protein	NULL
without	NULL
any	NULL
competitor	NULL
.	NULL

Lanes	NULL
5	NULL
,	NULL
6	NULL
,	NULL
and	NULL
13	NULL
through	NULL
20	NULL
show	NULL
competition	NULL
.	NULL

This	NULL
gel	NULL
was	NULL
run	NULL
for	NULL
5	NULL
V	NULL
/cm	NULL
for	NULL
12	NULL
hours	NULL
.	NULL

Band	NULL
A	NULL
is	NULL
the	NULL
low-mobility	NULL
complex	NULL
and	NULL
band	NULL
B	NULL
is	NULL
the	NULL
high-mobility	NULL
complex	NULL
.	NULL

The	NULL
area	NULL
at	NULL
the	NULL
bottom	NULL
of	NULL
the	NULL
lane	NULL
shows	NULL
the	NULL
free	NULL
probe	NULL
.	NULL

Patients	NULL
chosen	NULL
for	NULL
this	NULL
study	NULL
were	NULL
those	NULL
in	NULL
whom	NULL
the	NULL
responsiveness	NULL
to	NULL
IFN	NULL
could	NULL
be	NULL
determined	NULL
from	NULL
the	NULL
clinical	NULL
history	NULL
.	NULL

Patients	NULL
responding	NULL
to	NULL
a	NULL
combination	NULL
of	NULL
IFN-a	NULL
and	NULL
chemotherapy	NULL
were	NULL
excluded	NULL
from	NULL
analysis	NULL
in	NULL
Table	NULL
4	NULL
as	NULL
their	NULL
sensitivity	NULL
to	NULL
IFN-a	NULL
as	NULL
a	NULL
single	NULL
agent	NULL
was	NULL
incvaluable	NULL
.	NULL

The	NULL
analysis	NULL
and	NULL
interpretation	NULL
of	NULL
the	NULL
electrophoretic	NULL
mobility	NULL
analysis	NULL
of	NULL
nuclear	NULL
protein	NULL
DNA	NULL
complexes	NULL
were	NULL
performed	NULL
by	NULL
individuals	NULL
unfamiliar	NULL
with	NULL
the	NULL
IFN	NULL
response	NULL
status	NULL
.	NULL

Mobility-shift	NULL
analysis	NULL
.	NULL

Nuclear	NULL
proteins	NULL
were	NULL
isolated	NULL
from	NULL
peripheral	NULL
blood	NULL
cells	NULL
or	NULL
cell	NULL
lines	NULL
by	NULL
the	NULL
method	NULL
of	NULL
Miskimens	NULL
et	NULL
al	NULL
'	NULL
``	NULL
or	NULL
by	NULL
the	NULL
method	NULL
of	NULL
Dignam	NULL
et	NULL
al	NULL
.	NULL
``	NULL

The	NULL
mobility-shift	NULL
assay	NULL
was	NULL
performed	NULL
as	NULL
described	NULL
by	NULL
Treisman	NULL
,	NULL
``	NULL
except	NULL
that	NULL
the	NULL
binding	NULL
buffer	NULL
contained	NULL
120	NULL
mmol/L	NULL
NaCl	NULL
,	NULL
10	NULL
mmol/L	NULL
Tris	NULL
,	NULL
pH	NULL
7.5	NULL
,	NULL
20	NULL
mmol/L	NULL
2-mercaptoethanol	NULL
,	NULL
1	NULL
mmol/L	NULL
ethylenediamine	NULL
tetraacetate	NULL
,	NULL
4	NULL
%	NULL
glycerol	NULL
,	NULL
and	NULL
0.1	NULL
%	NULL
Triton	NULL
X-100	NULL
.	NULL

All	NULL
protein-binding	NULL
assays	NULL
were	NULL
performed	NULL
after	NULL
the	NULL
unfractionated	NULL
nuclear	NULL
proteins	NULL
(	NULL
2	NULL
to	NULL
12	NULL
ug	NULL
)	NULL
had	NULL
been	NULL
incubated	NULL
with	NULL
a	NULL
final	NULL
concentration	NULL
of	NULL
0.1	NULL
mg/mL	NULL
of	NULL
poly	NULL
(	NULL
dl	NULL
)	NULL
poly	NULL
(	NULL
dC	NULL
)	NULL
for	NULL
15	NULL
minutes	NULL
at	NULL
4°C	NULL
.	NULL

The	NULL
nuclear	NULL
proteins	NULL
were	NULL
then	NULL
exposed	NULL
for	NULL
1	NULL
hour	NULL
at	NULL
4°C	NULL
to	NULL
100	NULL
fmol	NULL
or	NULL
10°	NULL
cpm	NULL
of	NULL
the	NULL
transcription	NULL
enhancer	NULL
oligonucleotide	NULL
,	NULL
which	NULL
was	NULL
``	NULL
P	NULL
end-labeled	NULL
by	NULL
the	NULL
Klenow	NULL
reaction	NULL
.	NULL

The	NULL
nuclear	NULL
protein-DNA	NULL
complexes	NULL
were	NULL
electrophoresed	NULL
in	NULL
a	NULL
7.5	NULL
%	NULL
polyacrylamide	NULL
gel	NULL
at	NULL
5	NULL
V/cm	NULL
for	NULL
12	NULL
hours	NULL
in	NULL
a	NULL
Tris-acetate	NULL
buffer	NULL
.	NULL

Quantitation	NULL
of	NULL
the	NULL
high-	NULL
and	NULL
low-mobility	NULL
complexes	NULL
was	NULL
made	NULL
by	NULL
scanning	NULL
densitometry	NULL
.	NULL

Oligonucleotides	NULL
were	NULL
synthesized	NULL
in	NULL
the	NULL
M.D	NULL
.	NULL

Anderson	NULL
oligonucleotide	NULL
synthesis	NULL
core	NULL
laboratory	NULL
and	NULL
the	NULL
sequence	NULL
of	NULL
the	NULL
products	NULL
verified	NULL
by	NULL
Maxam-Gilbert	NULL
sequencing	NULL
reactions	NULL
.	NULL
``	NULL

Isolation	NULL
of	NULL
lymphocytes	NULL
and	NULL
monocytes	NULL
.	NULL

-	NULL
Peripheral	NULL
blood	NULL
mono-nuclear	NULL
cells	NULL
were	NULL
isolated	NULL
from	NULL
incidental	NULL
samples	NULL
obtained	NULL
from	NULL
routine	NULL
platelet	NULL
apheresis	NULL
.	NULL

Lymphocyte	NULL
and	NULL
monocyte	NULL
populations	NULL
were	NULL
isolated	NULL
by	NULL
centrifugal	NULL
elutriation	NULL
.	NULL

Monocyte	NULL
fractions	NULL
were	NULL
shown	NULL
to	NULL
be	NULL
over	NULL
95	NULL
%	NULL
monocytes	NULL
by	NULL
staining	NULL
with	NULL
alpha-naphthyl	NULL
butyrate	NULL
.	NULL

The	NULL
lymphocyte	NULL
fraction	NULL
was	NULL
determined	NULL
to	NULL
be	NULL
greater	NULL
than	NULL
95	NULL
%	NULL
lymphocytes	NULL
by	NULL
Giemsa	NULL
stain	NULL
.	NULL

RESULTS	NULL
Complexes	NULL
formed	NULL
between	NULL
interferon-inducible	NULL
transcriptional	NULL
enhancers	NULL
and	NULL
nuclear	NULL
proteins	NULL
from	NULL
lymphoid	NULL
or	NULL
myeloid	NULL
cells	NULL
.	NULL

We	NULL
used	NULL
the	NULL
mobility-shift	NULL
assay	NULL
to	NULL
study	NULL
From	NULL
www	NULL
.	NULL

bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

1120	NULL
the	NULL
electrophoretic	NULL
mobility	NULL
of	NULL
complexes	NULL
formed	NULL
between	NULL
nuclear	NULL
proteins	NULL
and	NULL
IFN-inducible	NULL
transcriptional	NULL
enhancers	NULL
.	NULL

The	NULL
nuclear	NULL
proteins	NULL
of	NULL
normal	NULL
monocytoid	NULL
cells	NULL
fraction-ated	NULL
from	NULL
normal	NULL
peripheral	NULL
blood	NULL
cells	NULL
form	NULL
a	NULL
high-mobility	NULL
complex	NULL
(	NULL
Fig	NULL
la	NULL
)	NULL
with	NULL
the	NULL
transcriptional	NULL
enhancers	NULL
of	NULL
the	NULL
IFN-inducible	NULL
gene	NULL
2,5-0AS	NULL
.	NULL

The	NULL
nuclear	NULL
proteins	NULL
from	NULL
normal	NULL
peripheral	NULL
blood	NULL
lymphoid	NULL
cells	NULL
form	NULL
a	NULL
low-mobility	NULL
complex	NULL
(	NULL
Fig	NULL
la	NULL
)	NULL
.	NULL

The	NULL
nuclear	NULL
proteins	NULL
isolated	NULL
from	NULL
lymphoid	NULL
cell	NULL
lines	NULL
(	NULL
Fig	NULL
1b	NULL
)	NULL
form	NULL
a	NULL
low-mobility	NULL
complex	NULL
with	NULL
the	NULL
2,5-0AS	NULL
IFN-inducible	NULL
transcriptional	NULL
enhancer	NULL
,	NULL
while	NULL
the	NULL
nuclear	NULL
proteins	NULL
of	NULL
myeloid	NULL
cell	NULL
lines	NULL
form	NULL
a	NULL
high-mobility	NULL
complex	NULL
(	NULL
Fig	NULL
1b	NULL
)	NULL
.	NULL

The	NULL
nuclear	NULL
proteins	NULL
of	NULL
lymphoid	NULL
and	NULL
myeloid	NULL
cells	NULL
formed	NULL
low-	NULL
or	NULL
high-mobility	NULL
complexes	NULL
,	NULL
respectively	NULL
,	NULL
with	NULL
the	NULL
IFN-inducible	NULL
transcriptional	NULL
enhancers	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
of	NULL
the	NULL
beta-2	NULL
microglobulin	NULL
and	NULL
the	NULL
6-16	NULL
,	NULL
9-27	NULL
,	NULL
and	NULL
2,5-0AS	NULL
genes	NULL
(	NULL
Fig	NULL
1C	NULL
)	NULL
.	NULL

Nuclear	NULL
proteins	NULL
from	NULL
monocytoid	NULL
cell	NULL
lines	NULL
formed	NULL
high-mobility	NULL
complexes	NULL
,	NULL
whereas	NULL
nuclear	NULL
proteins	NULL
from	NULL
erythroid	NULL
cells	NULL
(	NULL
HEL	NULL
,	NULL
K562	NULL
,	NULL
OCIM-2	NULL
)	NULL
formed	NULL
low-mobility	NULL
complexes	NULL
.	NULL

The	NULL
mRNA	NULL
levels	NULL
of	NULL
the	NULL
2,5-0A¥S	NULL
,	NULL
6-16	NULL
,	NULL
and	NULL
9-27	NULL
genes	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
IFN-inducible	NULL
in	NULL
myeloid	NULL
as	NULL
well	NULL
as	NULL
lymphoid	NULL
cells	NULL
in	NULL
our	NULL
own	NULL
laboratory	NULL
as	NULL
well	NULL
as	NULL
in	NULL
those	NULL
of	NULL
others	NULL
.	NULL
``	NULL

Sequence	NULL
specificity	NULL
of	NULL
nuclear	NULL
protein	NULL
binding	NULL
assay	NULL
.	NULL

We	NULL
incubated	NULL
nuclear	NULL
proteins	NULL
from	NULL
the	NULL
HL60	NULL
cell	NULL
line	NULL
,	NULL
which	NULL
forms	NULL
both	NULL
the	NULL
high-	NULL
and	NULL
low-mobility	NULL
complex	NULL
,	NULL
with	NULL
the	NULL
P	NULL
Klenow	NULL
end-labeled	NULL
2,5-O0AS	NULL
5	NULL
'	NULL
transcriptional	NULL
enhancer	NULL
oligonucleotide	NULL
(	NULL
Table	NULL
1	NULL
;	NULL
Fig	NULL
2	NULL
,	NULL
lane	NULL
21	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
unlabeled	NULL
oligonucleotides	NULL
that	NULL
were	NULL
homologous	NULL
or	NULL
nonhomologous	NULL
to	NULL
the	NULL
P-labeled	NULL
2,5-0AS	NULL
oligonucleotide	NULL
.	NULL

When	NULL
we	NULL
added	NULL
a	NULL
50-	NULL
or	NULL
100-fold	NULL
molar	NULL
excess	NULL
of	NULL
a	NULL
2,5-OAS	NULL
transcriptional	NULL
enhancer	NULL
oligonucleotide	NULL
itself	NULL
(	NULL
Fig	NULL
2	NULL
,	NULL
lanes	NULL
17	NULL
and	NULL
18	NULL
)	NULL
,	NULL
we	NULL
observed	NULL
almost	NULL
complete	NULL
inhibition	NULL
of	NULL
binding	NULL
of	NULL
nuclear	NULL
proteins	NULL
to	NULL
the	NULL
P-labeled	NULL
oligonucleotide	NULL
.	NULL

Addition	NULL
of	NULL
a	NULL
50-fold	NULL
excess	NULL
of	NULL
a	NULL
region	NULL
further	NULL
5	NULL
'	NULL
to	NULL
the	NULL
2,5-0AS	NULL
transcriptional	NULL
enhancer	NULL
(	NULL
Fig	NULL
2	NULL
,	NULL
lanes	NULL
19	NULL
and	NULL
20	NULL
)	NULL
,	NULL
which	NULL
contained	NULL
regions	NULL
homologous	NULL
to	NULL
the	NULL
``	NULL
P-labeled	NULL
2,5-0AS	NULL
transcriptional	NULL
enhancer	NULL
,	NULL
also	NULL
led	NULL
to	NULL
inhibition	NULL
of	NULL
binding	NULL
.	NULL

When	NULL
we	NULL
added	NULL
a	NULL
50-	NULL
or	NULL
a	NULL
100-fold	NULL
molar	NULL
excess	NULL
of	NULL
unlabeled	NULL
oligonucleotides	NULL
that	NULL
were	NULL
not	NULL
homologous	NULL
(	NULL
Fig	NULL
2	NULL
,	NULL
lanes	NULL
1	NULL
through	NULL
4	NULL
and	NULL
7	NULL
through	NULL
12	NULL
)	NULL
,	NULL
no	NULL
reduction	NULL
in	NULL
the	NULL
binding	NULL
of	NULL
nuclear	NULL
proteins	NULL
to	NULL
the	NULL
P-labeled	NULL
oligonucleotide	NULL
occurred	NULL
.	NULL

Addition	NULL
of	NULL
oligonucleotides	NULL
containing	NULL
elements	NULL
that	NULL
exhibited	NULL
homology	NULL
to	NULL
the	NULL
2,5-0AS	NULL
transcriptional	NULL
enhancer	NULL
oligonucleotide	NULL
showed	NULL
inhibition	NULL
of	NULL
binding	NULL
of	NULL
the	NULL
P-labeled	NULL
2,5-0AS	NULL
oligonucleotide	NULL
(	NULL
Fig	NULL
2	NULL
,	NULL
lanes	NULL
5	NULL
,	NULL
6	NULL
,	NULL
and	NULL
13	NULL
through	NULL
20	NULL
)	NULL
.	NULL

These	NULL
experiments	NULL
demonstrate	NULL
that	NULL
the	NULL
binding	NULL
of	NULL
nuclear	NULL
proteins	NULL
to	NULL
DNA	NULL
is	NULL
sequence-specific	NULL
under	NULL
the	NULL
conditions	NULL
of	NULL
our	NULL
experiments	NULL
.	NULL

Complexes	NULL
formed	NULL
between	NULL
the	NULL
interferon-inducible	NULL
transcriptional	NULL
enhancers	NULL
and	NULL
nuclear	NULL
proteins	NULL
extracted	NULL
from	NULL
chronic	NULL
myelogenous	NULL
leukemia	NULL
and	NULL
normal	NULL
cells	NULL
before	NULL
interferon	NULL
exposure	NULL
are	NULL
different	NULL
.	NULL

Nuclear	NULL
proteins	NULL
extracted	NULL
from	NULL
the	NULL
unfractionated	NULL
normal	NULL
peripheral	NULL
blood	NULL
cells	NULL
of	NULL
all	NULL
18	NULL
normal	NULL
donors	NULL
tested	NULL
formed	NULL
both	NULL
a	NULL
low-mobility	NULL
complex	NULL
and	NULL
a	NULL
high-mobility	NULL
complex	NULL
with	NULL
the	NULL
2,5-O0AS	NULL
oligonucleotide	NULL
(	NULL
Table	NULL
2	NULL
;	NULL
Fig	NULL
3a	NULL
)	NULL
.	NULL

HOWARD	NULL
ET	NULL
AL	NULL
The	NULL
nuclear	NULL
proteins	NULL
isolated	NULL
from	NULL
unfractionated	NULL
peripheral	NULL
blood	NULL
cells	NULL
of	NULL
all	NULL
44	NULL
CML	NULL
patients	NULL
tested	NULL
(	NULL
see	NULL
patient	NULL
data	NULL
in	NULL
Table	NULL
3	NULL
and	NULL
lane	NULL
1	NULL
of	NULL
Figs	NULL
3b	NULL
and	NULL
3¢	NULL
)	NULL
formed	NULL
the	NULL
high-mobility	NULL
complex	NULL
.	NULL

The	NULL
low-mobility	NULL
complex	NULL
was	NULL
undetectable	NULL
in	NULL
40	NULL
of	NULL
the	NULL
44	NULL
untreated	NULL
CML	NULL
samples	NULL
tested	NULL
(	NULL
see	NULL
Tables	NULL
2	NULL
and	NULL
3	NULL
and	NULL
lane	NULL
1	NULL
of	NULL
Figs	NULL
3b	NULL
and	NULL
3¢c	NULL
)	NULL
.	NULL

The	NULL
low-mobility	NULL
complex	NULL
was	NULL
undetectable	NULL
even	NULL
when	NULL
20	NULL
%	NULL
of	NULL
the	NULL
peripheral	NULL
blood	NULL
cells	NULL
were	NULL
lymphoid	NULL
(	NULL
patients	NULL
no	NULL
.	NULL

6	NULL
,	NULL
25	NULL
,	NULL
32	NULL
,	NULL
and	NULL
36	NULL
in	NULL
Table	NULL
3	NULL
)	NULL
.	NULL

In	NULL
vivo	NULL
exposure	NULL
to	NULL
alpha-interferon	NULL
alters	NULL
the	NULL
complexes	NULL
formed	NULL
between	NULL
interferon-inducible	NULL
transcriptional	NULL
enhancers	NULL
and	NULL
nuclear	NULL
proteins	NULL
.	NULL

-	NULL
We	NULL
then	NULL
studied	NULL
the	NULL
in	NULL
vivo	NULL
effect	NULL
of	NULL
IFN-	NULL
«	NULL
on	NULL
the	NULL
electrophoretic	NULL
mobility	NULL
of	NULL
complexes	NULL
formed	NULL
between	NULL
nuclear	NULL
proteins	NULL
isolated	NULL
from	NULL
the	NULL
unfractionated	NULL
peripheral	NULL
blood	NULL
cells	NULL
of	NULL
CML	NULL
patients	NULL
and	NULL
IFN-inducible	NULL
transcriptional	NULL
enhancers	NULL
.	NULL

The	NULL
CML	NULL
patients	NULL
we	NULL
studied	NULL
exhibited	NULL
the	NULL
following	NULL
different	NULL
clinical	NULL
response	NULL
patterns	NULL
to	NULL
IFN-a	NULL
,	NULL
which	NULL
indicate	NULL
different	NULL
levels	NULL
of	NULL
sensitivity	NULL
to	NULL
IFN-a	NULL
:	NULL
complete	NULL
or	NULL
partial	NULL
hematologic	NULL
remissions	NULL
(	NULL
Table	NULL
4	NULL
)	NULL
,	NULL
partial	NULL
cytogenetic	NULL
remissions	NULL
(	NULL
Table	NULL
5	NULL
)	NULL
,	NULL
complete	NULL
cytogenetic	NULL
remissions	NULL
(	NULL
Table	NULL
6	NULL
)	NULL
,	NULL
primary	NULL
or	NULL
de	NULL
novo	NULL
resistance	NULL
defined	NULL
as	NULL
failure	NULL
of	NULL
IFN	NULL
to	NULL
decrease	NULL
the	NULL
white	NULL
blood	NULL
cell	NULL
count	NULL
to	NULL
below	NULL
20,000/mm*	NULL
in	NULL
3	NULL
months	NULL
of	NULL
therapy	NULL
(	NULL
Table	NULL
7	NULL
)	NULL
,	NULL
and	NULL
secondary	NULL
resistance	NULL
(	NULL
the	NULL
loss	NULL
of	NULL
hematologic	NULL
or	NULL
cytogenetic	NULL
remission	NULL
)	NULL
while	NULL
receiving	NULL
IFN-	NULL
(	NULL
Table	NULL
7	NULL
)	NULL
.	NULL

The	NULL
patients	NULL
were	NULL
usually	NULL
treated	NULL
3	NULL
to	NULL
6	NULL
months	NULL
before	NULL
the	NULL
response	NULL
status	NULL
was	NULL
defined	NULL
.	NULL

Interferon	NULL
antibodies	NULL
were	NULL
ruled	NULL
out	NULL
as	NULL
a	NULL
cause	NULL
of	NULL
clinical	NULL
resistance	NULL
in	NULL
all	NULL
resistant	NULL
patients	NULL
included	NULL
in	NULL
this	NULL
study	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
lane	NULL
2	NULL
of	NULL
Fig	NULL
3b	NULL
,	NULL
when	NULL
the	NULL
nuclear	NULL
proteins	NULL
were	NULL
extracted	NULL
from	NULL
the	NULL
unfractionated	NULL
peripheral	NULL
blood	NULL
cells	NULL
of	NULL
IFN-sensitive	NULL
CML	NULL
patients	NULL
during	NULL
IFN	NULL
therapy	NULL
,	NULL
both	NULL
low-	NULL
and	NULL
high-mobility	NULL
complexes	NULL
were	NULL
detected	NULL
in	NULL
10	NULL
of	NULL
Table	NULL
2	NULL
.	NULL

Interferon-induced	NULL
Changes	NULL
in	NULL
Nuclear	NULL
Protein	NULL
Binding	NULL
Correlate	NULL
With	NULL
Clinical	NULL
Sensitivity	NULL
Percent	NULL
of	NULL
Patients	NULL
Whose	NULL
Proteins	NULL
Form	NULL
the	NULL
Low-Mobility	NULL
Complex	NULL
(	NULL
Patient	NULL
Nos	NULL
.	NULL

Patients	NULL
in	NULL
Parenthesis	NULL
)	NULL
Normal	NULL
100	NULL
(	NULL
18/18	NULL
)	NULL
CML	NULL
off	NULL
IFN	NULL
10	NULL
(	NULL
4/44	NULL
)	NULL
Sensitive	NULL
CML	NULL
on	NULL
interferon	NULL
97	NULL
(	NULL
28/29	NULL
)	NULL
Hematologic	NULL
responders	NULL
on	NULL
IFN	NULL
(	NULL
10/10	NULL
)	NULL
Partial	NULL
cytogenetic	NULL
responders	NULL
on	NULL
IFN	NULL
(	NULL
11/12	NULL
)	NULL
Complete	NULL
cytogenetic	NULL
responders	NULL
(	NULL
100	NULL
%	NULL
diploid	NULL
)	NULL
(	NULL
7/7	NULL
)	NULL
IFN-resistant	NULL
(	NULL
primary	NULL
or	NULL
secondary	NULL
}	NULL
patients	NULL
on	NULL
IFN	NULL
9	NULL
(	NULL
1/13	NULL
)	NULL
The	NULL
fraction	NULL
(	NULL
28	NULL
of	NULL
29	NULL
)	NULL
of	NULL
the	NULL
IFN-sensitive	NULL
CML	NULL
patients	NULL
receiving	NULL
IFN	NULL
whose	NULL
nuclear	NULL
proteins	NULL
form	NULL
the	NULL
low-mobility	NULL
complex	NULL
(	NULL
10	NULL
of	NULL
10	NULL
hematologic	NULL
responders	NULL
,	NULL
11	NULL
of	NULL
12	NULL
partial	NULL
responders	NULL
,	NULL
and	NULL
seven	NULL
of	NULL
seven	NULL
complete	NULL
cytogenetic	NULL
responders	NULL
)	NULL
is	NULL
statistically	NULL
different	NULL
(	NULL
P	NULL
=	NULL
.01	NULL
)	NULL
from	NULL
the	NULL
fraction	NULL
of	NULL
CML	NULL
patients	NULL
off	NULL
of	NULL
IFN	NULL
whose	NULL
nuclear	NULL
proteins	NULL
form	NULL
the	NULL
low-mobility	NULL
complex	NULL
{	NULL
four	NULL
of	NULL
44	NULL
)	NULL
.	NULL

The	NULL
fraction	NULL
(	NULL
28	NULL
of	NULL
29	NULL
)	NULL
of	NULL
the	NULL
IFN-sensitive	NULL
CML	NULL
patients	NULL
receiving	NULL
IFN	NULL
whose	NULL
proteins	NULL
form	NULL
the	NULL
fow-mobility	NULL
complex	NULL
is	NULL
statistically	NULL
different	NULL
(	NULL
P	NULL
=	NULL
.01	NULL
)	NULL
from	NULL
the	NULL
fraction	NULL
of	NULL
IFN-resistant	NULL
CML	NULL
patients	NULL
receiving	NULL
IFN	NULL
whose	NULL
nuclear	NULL
proteins	NULL
form	NULL
the	NULL
low-mobility	NULL
complex	NULL
(	NULL
one	NULL
of	NULL
13	NULL
)	NULL
.	NULL

From	NULL
www	NULL
.	NULL

bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

INTERFERON	NULL
AND	NULL
NUCLEAR	NULL
PROTEINS	NULL
IN	NULL
CML	NULL
Wol	NULL
-	NULL
llis	NULL
a-	NULL
A	NULL
B	NULL
a	NULL
12	NULL
b	NULL
1121	NULL
C	NULL
Fig	NULL
3	NULL
.	NULL

-	NULL
Complexes	NULL
formed	NULL
between	NULL
IFN-inducible	NULL
transcriptional	NULL
enhancer	NULL
and	NULL
the	NULL
nuclear	NULL
protein	NULL
of	NULL
peripheral	NULL
blood	NULL
cells	NULL
before	NULL
and	NULL
after	NULL
in	NULL
vivo	NULL
exposure	NULL
to	NULL
IFN-a	NULL
.	NULL

(	NULL
a	NULL
)	NULL
Gel	NULL
mobility-shift	NULL
analysis	NULL
of	NULL
complexes	NULL
formed	NULL
between	NULL
the	NULL
2,5-O0AS	NULL
transcriptional	NULL
enhancer	NULL
and	NULL
the	NULL
nuclear	NULL
proteins	NULL
isolated	NULL
from	NULL
the	NULL
unfractionated	NULL
peripheral	NULL
blood	NULL
cells	NULL
of	NULL
e	NULL
normal	NULL
individual	NULL
(	NULL
lane	NULL
1	NULL
}	NULL
,	NULL
which	NULL
forms	NULL
both	NULL
the	NULL
high	NULL
(	NULL
band	NULL
B	NULL
)	NULL
-and	NULL
low	NULL
(	NULL
band	NULL
A	NULL
)	NULL
-mobility	NULL
pl	NULL
Lane	NULL
2	NULL
ins	NULL
a	NULL
plex	NULL
formed	NULL
by	NULL
nuclear	NULL
proteins	NULL
,	NULL
which	NULL
form	NULL
only	NULL
the	NULL
low-mobility	NULL
complex	NULL
(	NULL
band	NULL
A	NULL
)	NULL
provided	NULL
as	NULL
an	NULL
electrophoretic	NULL
mobility	NULL
marker	NULL
.	NULL

(	NULL
b	NULL
)	NULL
Gel	NULL
mobility-shift	NULL
analysis	NULL
of	NULL
complexes	NULL
formed	NULL
between	NULL
the	NULL
2,5-0AS	NULL
transcriptional	NULL
enhancer	NULL
and	NULL
the	NULL
nuclear	NULL
proteins	NULL
of	NULL
an	NULL
IFN-sensitive	NULL
CML	NULL
patient	NULL
before	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
and	NULL
after	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
in	NULL
vivo	NULL
exposure	NULL
to	NULL
daily	NULL
subcutaneous	NULL
injections	NULL
of	NULL
IFN-a	NULL
(	NULL
overexposure	NULL
of	NULL
the	NULL
autoradiograph	NULL
does	NULL
not	NULL
reveal	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
low-mobility	NULL
complex	NULL
in	NULL
lane	NULL
1	NULL
)	NULL
.	NULL

(	NULL
c	NULL
)	NULL
Gel	NULL
mobility-shift	NULL
analysis	NULL
of	NULL
complex	NULL
(	NULL
band	NULL
B	NULL
)	NULL
formed	NULL
between	NULL
the	NULL
2,5-O0AS	NULL
transcriptional	NULL
enhancer	NULL
and	NULL
the	NULL
nuclear	NULL
proteins	NULL
of	NULL
an	NULL
IFN-resistant	NULL
CML	NULL
patient	NULL
after	NULL
in	NULL
vivo	NULL
exposure	NULL
to	NULL
daily	NULL
subcutaneous	NULL
injection	NULL
of	NULL
interferon	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
.	NULL

The	NULL
complex	NULL
formed	NULL
between	NULL
the	NULL
nuclear	NULL
proteins	NULL
of	NULL
a	NULL
lymphoid	NULL
cell	NULL
line	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
,	NULL
which	NULL
form	NULL
only	NULL
the	NULL
low-mobility	NULL
complex	NULL
with	NULL
the	NULL
interferon-inducible	NULL
transcription	NULL
enhancer	NULL
,	NULL
is	NULL
shown	NULL
as	NULL
an	NULL
electrophoretic	NULL
mobility	NULL
marker	NULL
for	NULL
the	NULL
low-mobility	NULL
complex	NULL
(	NULL
band	NULL
A	NULL
)	NULL
.	NULL

Lane	NULL
1	NULL
shows	NULL
the	NULL
complex	NULL
of	NULL
an	NULL
untreated	NULL
CML	NULL
patient	NULL
as	NULL
a	NULL
marker	NULL
for	NULL
the	NULL
high-mobility	NULL
complex	NULL
(	NULL
band	NULL
B	NULL
)	NULL
.	NULL

The	NULL
gels	NULL
were	NULL
run	NULL
at	NULL
5	NULL
V/cm	NULL
for	NULL
12	NULL
hours	NULL
.	NULL

Band	NULL
A	NULL
is	NULL
the	NULL
low-mobility	NULL
complex	NULL
and	NULL
band	NULL
B	NULL
is	NULL
the	NULL
high-mobility	NULL
complex	NULL
.	NULL

The	NULL
area	NULL
at	NULL
the	NULL
bottom	NULL
of	NULL
each	NULL
lane	NULL
contains	NULL
the	NULL
unbound	NULL
probe	NULL
.	NULL

10	NULL
chronic	NULL
phase	NULL
CML	NULL
patients	NULL
(	NULL
patients	NULL
no	NULL
.	NULL

4	NULL
and	NULL
45	NULL
through	NULL
53	NULL
in	NULL
Table	NULL
4	NULL
)	NULL
who	NULL
had	NULL
developed	NULL
a	NULL
complete	NULL
or	NULL
partial	NULL
hematologic	NULL
remission	NULL
on	NULL
5	NULL
to	NULL
10	NULL
x	NULL
10°	NULL
U/d	NULL
subcutaneous	NULL
injections	NULL
of	NULL
IFN-a	NULL
(	NULL
Table	NULL
2	NULL
)	NULL
.	NULL

This	NULL
result	NULL
contrasts	NULL
with	NULL
the	NULL
absence	NULL
of	NULL
the	NULL
low-mobility	NULL
complex	NULL
when	NULL
the	NULL
nuclear	NULL
protein	NULL
is	NULL
extracted	NULL
from	NULL
the	NULL
unfractionated	NULL
peripheral	NULL
blood	NULL
cells	NULL
of	NULL
the	NULL
same	NULL
CML	NULL
patients	NULL
during	NULL
a	NULL
period	NULL
when	NULL
they	NULL
were	NULL
not	NULL
being	NULL
treated	NULL
with	NULL
IFN-a	NULL
(	NULL
Tables	NULL
2	NULL
and	NULL
3	NULL
and	NULL
lane	NULL
1	NULL
of	NULL
Fig	NULL
3b	NULL
)	NULL
.	NULL

The	NULL
nuclear	NULL
proteins	NULL
extracted	NULL
from	NULL
the	NULL
unfractionated	NULL
IFN-exposed	NULL
peripheral	NULL
blood	NULL
cells	NULL
of	NULL
CML	NULL
partial	NULL
(	NULL
patients	NULL
no	NULL
.	NULL

7	NULL
and	NULL
54	NULL
through	NULL
64	NULL
in	NULL
Table	NULL
5	NULL
)	NULL
or	NULL
complete	NULL
(	NULL
patients	NULL
no	NULL
.	NULL

65	NULL
through	NULL
71	NULL
in	NULL
Table	NULL
6	NULL
)	NULL
cytogenetic	NULL
remitters	NULL
also	NULL
formed	NULL
the	NULL
low-mobility	NULL
complex	NULL
with	NULL
the	NULL
transcriptional	NULL
enhancers	NULL
of	NULL
IFN-inducible	NULL
genes	NULL
.	NULL

This	NULL
occurred	NULL
in	NULL
18	NULL
of	NULL
19	NULL
cases	NULL
tested	NULL
:	NULL
11	NULL
of	NULL
12	NULL
partial	NULL
cytogenetic	NULL
responders	NULL
and	NULL
seven	NULL
of	NULL
seven	NULL
complete	NULL
cytogenetic	NULL
responders	NULL
(	NULL
Table	NULL
2	NULL
)	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Tables	NULL
2	NULL
and	NULL
7	NULL
,	NULL
the	NULL
nuclear	NULL
proteins	NULL
extracted	NULL
from	NULL
peripheral	NULL
blood	NULL
cells	NULL
of	NULL
IFN-resistant	NULL
CML	NULL
patients	NULL
did	NULL
not	NULL
form	NULL
the	NULL
low-mobility	NULL
complex	NULL
when	NULL
exposed	NULL
in	NULL
vivo	NULL
to	NULL
IFN-a	NULL
,	NULL
as	NULL
shown	NULL
in	NULL
lane	NULL
2	NULL
of	NULL
Fig	NULL
3¢c	NULL
.	NULL

The	NULL
low-mobility	NULL
complex	NULL
formed	NULL
in	NULL
only	NULL
one	NULL
of	NULL
13	NULL
cases	NULL
(	NULL
patients	NULL
no	NULL
.	NULL

17	NULL
through	NULL
19	NULL
,	NULL
21	NULL
,	NULL
22	NULL
,	NULL
26	NULL
,	NULL
28	NULL
,	NULL
31	NULL
,	NULL
34	NULL
,	NULL
35	NULL
,	NULL
and	NULL
72	NULL
through	NULL
74	NULL
in	NULL
Table	NULL
7	NULL
)	NULL
.	NULL

The	NULL
difference	NULL
between	NULL
the	NULL
numbers	NULL
of	NULL
IFN-resistant	NULL
and	NULL
-sensitive	NULL
CML	NULL
patients	NULL
whose	NULL
unfractionated	NULL
peripheral	NULL
blood	NULL
cells	NULL
are	NULL
sensitive	NULL
to	NULL
the	NULL
IFN-induced	NULL
effect	NULL
on	NULL
nuclear	NULL
protein	NULL
complexes	NULL
is	NULL
statistically	NULL
significant	NULL
(	NULL
P	NULL
=	NULL
.01	NULL
)	NULL
.	NULL

This	NULL
difference	NULL
is	NULL
shown	NULL
in	NULL
Table	NULL
2	NULL
.	NULL

In	NULL
vitro	NULL
effect	NULL
of	NULL
alpha-interferon	NULL
on	NULL
nuclear	NULL
proteins	NULL
that	NULL
bind	NULL
to	NULL
interferon-inducible	NULL
transcriptional	NULL
enhancers	NULL
.	NULL

-	NULL
We	NULL
exposed	NULL
unfractionated	NULL
peripheral	NULL
blood	NULL
cells	NULL
,	NULL
from	NULL
a	NULL
CML	NULL
patient	NULL
who	NULL
exhibited	NULL
IFN	NULL
sensitivity	NULL
at	NULL
the	NULL
time	NULL
of	NULL
the	NULL
assay	NULL
,	NULL
in	NULL
vitro	NULL
,	NULL
to	NULL
1,000	NULL
U/mL	NULL
of	NULL
IFN-a	NULL
for	NULL
1	NULL
hour	NULL
at	NULL
37°C	NULL
.	NULL

As	NULL
shown	NULL
by	NULL
a	NULL
comparison	NULL
of	NULL
the	NULL
mobility-shift	NULL
assay	NULL
of	NULL
the	NULL
1122	NULL
From	NULL
www	NULL
.	NULL

bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

HOWARD	NULL
ET	NULL
AL	NULL
Table	NULL
3	NULL
.	NULL

Analysis	NULL
of	NULL
Nuclear	NULL
Proteins	NULL
Extracted	NULL
From	NULL
Unfractionated	NULL
Peripheral	NULL
Blood	NULL
Cells	NULL
of	NULL
Chronic	NULL
Myelogenous	NULL
Leukemia	NULL
Patients	NULL
:	NULL
Samples	NULL
Collected	NULL
While	NULL
Off	NULL
of	NULL
Interferon	NULL
%	NULL
Low-Mobility	NULL
Patient	NULL
Complex®	NULL
Sensitivity	NULL
No	NULL
.	NULL

Date	NULL
{	NULL
Band	NULL
A	NULL
}	NULL
to	NULL
IFN	NULL
%	NULL
Ph+	NULL
Comments	NULL
1	NULL
9/30/88	NULL
0	NULL
S	NULL
100	NULL
Went	NULL
into	NULL
complete	NULL
hematologic	NULL
remission	NULL
4/4/88	NULL
on	NULL
IFN	NULL
alone	NULL
2	NULL
4/7/88	NULL
0	NULL
S	NULL
100	NULL
Went	NULL
into	NULL
complete	NULL
hematologic	NULL
remission	NULL
on	NULL
IFN-3	NULL
9/6/88	NULL
4	NULL
S	NULL
100	NULL
Partial	NULL
hematologic	NULL
remission	NULL
on	NULL
IFN-	NULL
«	NULL
4	NULL
1/6/88	NULL
0	NULL
S	NULL
100	NULL
Initially	NULL
sensitive	NULL
,	NULL
then	NULL
evolved	NULL
into	NULL
secondary	NULL
resistance	NULL
5	NULL
11/8/88	NULL
0	NULL
S	NULL
t	NULL
Hematologic	NULL
remission	NULL
on	NULL
ara-C	NULL
and	NULL
IFN-a	NULL
6	NULL
2/22/88	NULL
0	NULL
rS	NULL
100	NULL
Complete	NULL
hematologic	NULL
remission	NULL
on	NULL
IFN-a	NULL
and	NULL
ara-C	NULL
(	NULL
1	NULL
course	NULL
of	NULL
ara-C	NULL
)	NULL
and	NULL
was	NULL
maintained	NULL
in	NULL
CHR	NULL
for	NULL
1	NULL
year	NULL
on	NULL
IFN	NULL
only	NULL
7	NULL
6/28/88	NULL
0	NULL
S	NULL
100	NULL
Developed	NULL
complete	NULL
cytogenetic	NULL
response	NULL
on	NULL
IFN-	NULL
;	NULL
sample	NULL
taken	NULL
before	NULL
therapy	NULL
8	NULL
5/17/88	NULL
0	NULL
S	NULL
96	NULL
Went	NULL
into	NULL
complete	NULL
cytogenetic	NULL
remission	NULL
on	NULL
IFN-a	NULL
9	NULL
5/17/88	NULL
0	NULL
S	NULL
100	NULL
Developed	NULL
a	NULL
complete	NULL
cytogenetic	NULL
remission	NULL
in	NULL
3	NULL
mo	NULL
of	NULL
IFN	NULL
therapy	NULL
10	NULL
8/3/88	NULL
0	NULL
S	NULL
100	NULL
Sample	NULL
taken	NULL
at	NULL
start	NULL
of	NULL
therapy	NULL
;	NULL
partial	NULL
cytogenetic	NULL
remission	NULL
on	NULL
IFN-a	NULL
11	NULL
8/24/88	NULL
0	NULL
S	NULL
96	NULL
Ultimately	NULL
developed	NULL
partial	NULL
cytogenetic	NULL
remission	NULL
12	NULL
2/22/88	NULL
0	NULL
S	NULL
{	NULL
clonal	NULL
100	NULL
Achieved	NULL
partial	NULL
hematologic	NULL
remission	NULL
on	NULL
IFN-a	NULL
,	NULL
had	NULL
clonal	NULL
evolution	NULL
at	NULL
diag-evolution	NULL
)	NULL
nosis	NULL
13	NULL
11/1/88	NULL
0	NULL
S	NULL
100	NULL
Went	NULL
into	NULL
complete	NULL
hematologic	NULL
remission	NULL
on	NULL
IFN	NULL
14	NULL
7/29/88	NULL
0	NULL
S	NULL
Variant	NULL
of	NULL
Ph	NULL
Achieved	NULL
a	NULL
complete	NULL
hematologic	NULL
remission	NULL
on	NULL
IFN-chromosome	NULL
100	NULL
%	NULL
15	NULL
9/20/88	NULL
0	NULL
S	NULL
100	NULL
Eventually	NULL
achieved	NULL
complete	NULL
hematologic	NULL
remission	NULL
on	NULL
IFN-a	NULL
;	NULL
sample	NULL
taken	NULL
at	NULL
start	NULL
16	NULL
11/10/88	NULL
21	NULL
S	NULL
100	NULL
Entered	NULL
complete	NULL
hematologic	NULL
remission	NULL
on	NULL
IFN	NULL
17	NULL
10/10/88	NULL
0	NULL
1°R	NULL
100	NULL
Primary	NULL
resistance	NULL
18	NULL
6/21/88	NULL
0	NULL
1°R	NULL
88	NULL
Primary	NULL
resistance	NULL
19	NULL
6/13/88	NULL
0	NULL
1°R	NULL
100	NULL
Primary	NULL
resistance	NULL
20	NULL
9/14/88	NULL
0	NULL
1°R	NULL
100	NULL
(	NULL
clonal	NULL
Primary	NULL
resistance	NULL
evolution	NULL
)	NULL
21	NULL
3/18/88	NULL
0	NULL
1°R	NULL
100	NULL
Primary	NULL
resistance	NULL
22	NULL
3/28/88	NULL
0	NULL
1°R	NULL
100	NULL
Primary	NULL
resistance	NULL
to	NULL
IFN-e	NULL
23	NULL
4/18/88	NULL
0	NULL
1°R	NULL
100	NULL
Primary	NULL
resistance	NULL
24	NULL
8/15/88	NULL
0	NULL
1°R	NULL
100	NULL
Primary	NULL
resistance	NULL
to	NULL
IFN-	NULL
«	NULL
25	NULL
12/16/88	NULL
0	NULL
1°R	NULL
100	NULL
Primary	NULL
resistance	NULL
;	NULL
required	NULL
hydroxyurea	NULL
to	NULL
control	NULL
counts	NULL
while	NULL
on	NULL
ara-C	NULL
and	NULL
IFN-26	NULL
5/4/88	NULL
0	NULL
1°R	NULL
100	NULL
Primary	NULL
resistance	NULL
to	NULL
IFN-a	NULL
and	NULL
-y	NULL
27	NULL
3/14/88	NULL
52	NULL
1°R	NULL
(	NULL
gamma	NULL
)	NULL
100	NULL
Counts	NULL
controlled	NULL
but	NULL
spleen	NULL
increased	NULL
on	NULL
IFN-y	NULL
;	NULL
counts	NULL
cycled	NULL
on	NULL
IFN-a	NULL
;	NULL
in-INE	NULL
(	NULL
alpha	NULL
}	NULL
adequate	NULL
trial	NULL
due	NULL
to	NULL
thrombocytopenia	NULL
;	NULL
hydroxyurea	NULL
used	NULL
to	NULL
put	NULL
patient	NULL
into	NULL
CHR	NULL
at	NULL
time	NULL
of	NULL
sample	NULL
28	NULL
2/16/88	NULL
0	NULL
1°R	NULL
mitotic	NULL
calls	NULL
No	NULL
Primary	NULL
resistance	NULL
to	NULL
interferon-a	NULL
and	NULL
-y	NULL
29	NULL
2/18/88	NULL
0	NULL
1°R	NULL
100	NULL
Evolved	NULL
into	NULL
blast	NULL
crisis	NULL
on	NULL
IFN-a	NULL
and	NULL
hydroxyurea	NULL
30	NULL
5/23/88	NULL
0	NULL
2°R	NULL
100	NULL
Developed	NULL
accelerated	NULL
phase	NULL
31	NULL
2/17/88	NULL
0	NULL
2°R	NULL
100	NULL
Secondary	NULL
resistance	NULL
acquired	NULL
on	NULL
IFN-a	NULL
32	NULL
9/28/88	NULL
0	NULL
2°R	NULL
100	NULL
Developed	NULL
resistance	NULL
after	NULL
partial	NULL
cytogenetic	NULL
remission	NULL
on	NULL
ara-C	NULL
and	NULL
IFN	NULL
33	NULL
4/7/88	NULL
0	NULL
2°R	NULL
100	NULL
Evolving	NULL
to	NULL
blast	NULL
crisis	NULL
;	NULL
IFN	NULL
resistant	NULL
34	NULL
5/19/88	NULL
0	NULL
2°R	NULL
100	NULL
Evolved	NULL
to	NULL
accelerated	NULL
phase	NULL
35	NULL
5/3/88	NULL
4	NULL
2°R	NULL
100	NULL
Secondary	NULL
resistance	NULL
,	NULL
required	NULL
hydroxyurea	NULL
36	NULL
5/9/88	NULL
0	NULL
INE	NULL
100	NULL
Major	NULL
cytogenetic	NULL
response	NULL
to	NULL
IFN-a	NULL
and	NULL
ara-C	NULL
;	NULL
sample	NULL
taken	NULL
before	NULL
therapy	NULL
37	NULL
5/26/88	NULL
d	NULL
INE	NULL
100	NULL
Required	NULL
ara-C	NULL
at	NULL
increased	NULL
doses	NULL
and	NULL
IFN	NULL
to	NULL
decrease	NULL
WBC	NULL
;	NULL
reached	NULL
a	NULL
partial	NULL
cytogenetic	NULL
ission	NULL
2/88	NULL
;	NULL
i	NULL
luable	NULL
for	NULL
IFN	NULL
resp	NULL
38	NULL
4/7/88	NULL
0	NULL
INE	NULL
100	NULL
Treated	NULL
with	NULL
IFN/ara-C	NULL
;	NULL
inevaluable	NULL
for	NULL
IFN	NULL
sensitivity	NULL
,	NULL
but	NULL
developed	NULL
minor	NULL
cytogenetic	NULL
response	NULL
;	NULL
sample	NULL
from	NULL
2/29/88	NULL
was	NULL
64	NULL
%	NULL
low-mobility	NULL
complex	NULL
and	NULL
taken	NULL
while	NULL
patient	NULL
was	NULL
off	NULL
of	NULL
IFN	NULL
39	NULL
11/8/88	NULL
0	NULL
INE	NULL
100	NULL
Invaluable	NULL
since	NULL
on	NULL
IFN	NULL
and	NULL
hydroxyurea	NULL
40	NULL
4/4/88	NULL
0	NULL
INE	NULL
100	NULL
Achieved	NULL
complete	NULL
hematologic	NULL
remission	NULL
on	NULL
IFN-	NULL
and	NULL
hydroxyurea	NULL
;	NULL
sample	NULL
taken	NULL
before	NULL
therapy	NULL
41	NULL
8/25/88	NULL
0	NULL
INE	NULL
{	NULL
clonal	NULL
100	NULL
Treated	NULL
with	NULL
hydroxyurea	NULL
and	NULL
IFN	NULL
evolution	NULL
)	NULL
42	NULL
10/23/88	NULL
0	NULL
INE	NULL
100	NULL
Developed	NULL
complete	NULL
hematologic	NULL
remission	NULL
on	NULL
IFN-a	NULL
plus	NULL
hydroxyurea	NULL
;	NULL
inevaluable	NULL
for	NULL
IFN	NULL
sensitivity	NULL
43	NULL
3/22/88	NULL
0	NULL
INE	NULL
100	NULL
3-Month	NULL
trial	NULL
of	NULL
IFN-a	NULL
stopped	NULL
due	NULL
to	NULL
toxicity	NULL
44	NULL
9/20/88	NULL
0	NULL
INE	NULL
100	NULL
Treated	NULL
with	NULL
DOAP	NULL
;	NULL
sample	NULL
drawn	NULL
during	NULL
recovery	NULL
from	NULL
chemotherapy	NULL
Abbreviations	NULL
:	NULL
Ph	NULL
,	NULL
Philadelphia	NULL
chromosome	NULL
;	NULL
CHR	NULL
,	NULL
complete	NULL
hematological	NULL
remission	NULL
;	NULL
S	NULL
,	NULL
sensitivity	NULL
;	NULL
1°R	NULL
,	NULL
primary	NULL
resistance	NULL
;	NULL
2°R	NULL
,	NULL
secondary	NULL
resistance	NULL
;	NULL
INE	NULL
,	NULL
inevaluable	NULL
;	NULL
WBC	NULL
,	NULL
white	NULL
blood	NULL
cell	NULL
count	NULL
;	NULL
DOAP	NULL
,	NULL
daunomycin	NULL
,	NULL
oncovin	NULL
,	NULL
ara-C	NULL
,	NULL
and	NULL
prednisone	NULL
.	NULL

*	NULL
%	NULL
Low-mobility	NULL
complex	NULL
,	NULL
low-mobility	NULL
complex	NULL
(	NULL
band	NULL
A	NULL
)	NULL
/low	NULL
(	NULL
A	NULL
)	NULL
-	NULL
and	NULL
high	NULL
(	NULL
B	NULL
}	NULL
-mobility	NULL
complex	NULL
x	NULL
100	NULL
,	NULL
as	NULL
determined	NULL
by	NULL
scanning	NULL
densitometry	NULL
of	NULL
autoradiographs	NULL
of	NULL
mobility-shift	NULL
assays	NULL
.	NULL

These	NULL
were	NULL
performed	NULL
to	NULL
estimate	NULL
the	NULL
percent	NULL
of	NULL
the	NULL
nuclear	NULL
proteins	NULL
bound	NULL
to	NULL
the	NULL
IFN-inducible	NULL
regulatory	NULL
element	NULL
which	NULL
are	NULL
involved	NULL
in	NULL
the	NULL
low-mobility	NULL
complex	NULL
versus	NULL
the	NULL
high-mobility	NULL
complex	NULL
.	NULL

4Patient	NULL
no	NULL
.	NULL

5	NULL
was	NULL
Philadelphia	NULL
chromosome	NULL
negative	NULL
at	NULL
diagnosis	NULL
,	NULL
but	NULL
positive	NULL
for	NULL
a	NULL
chimeric	NULL
ber-abl	NULL
gene	NULL
by	NULL
Southern	NULL
analysis	NULL
.	NULL

From	NULL
www	NULL
.	NULL

bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

INTERFERON	NULL
AND	NULL
NUCLEAR	NULL
PROTEINS	NULL
IN	NULL
CML	NULL
1123	NULL
Table	NULL
4	NULL
.	NULL

Analysis	NULL
of	NULL
Nuclear	NULL
Proteins	NULL
Extracted	NULL
From	NULL
Unfractionated	NULL
Peripheral	NULL
Blood	NULL
Cells	NULL
of	NULL
Chronic	NULL
Myelogenous	NULL
Leukemia	NULL
Patients	NULL
Who	NULL
Are	NULL
Hematologic	NULL
Responders	NULL
:	NULL
Samples	NULL
Collected	NULL
While	NULL
Receiving	NULL
IFN	NULL
Time	NULL
Elapsed	NULL
%	NULL
Low-Mobility	NULL
Between	NULL
Initiation	NULL
Clinical	NULL
Patient	NULL
Complex	NULL
of	NULL
Therapy	NULL
and	NULL
Sensitivity	NULL
%	NULL
No	NULL
.	NULL

Date	NULL
(	NULL
Band	NULL
A	NULL
)	NULL
Sample	NULL
Collection	NULL
to	NULL
IFN	NULL
Ph+	NULL
Comments	NULL
Interferon	NULL
hematologic	NULL
responders	NULL
who	NULL
are	NULL
100	NULL
%	NULL
Ph+	NULL
4	NULL
1/20/88	NULL
100	NULL
4	NULL
yr	NULL
,	NULL
5	NULL
mo	NULL
S	NULL
100	NULL
Achieved	NULL
CHR	NULL
and	NULL
10	NULL
%	NULL
Ph-	NULL
cells	NULL
4	NULL
years	NULL
after	NULL
diagnosis	NULL
on	NULL
IFN-	NULL
«	NULL
,	NULL
which	NULL
was	NULL
subsequently	NULL
lost	NULL
by	NULL
10/88	NULL
45	NULL
2/12/88	NULL
100	NULL
37	NULL
mo	NULL
S	NULL
100	NULL
Reached	NULL
complete	NULL
hematologic	NULL
remission	NULL
on	NULL
IFN-a	NULL
alone	NULL
46	NULL
11/7/88	NULL
21	NULL
7	NULL
mo	NULL
S	NULL
100	NULL
Reached	NULL
complete	NULL
hematologic	NULL
remission	NULL
in	NULL
6	NULL
mo	NULL
on	NULL
IFN-a	NULL
alone	NULL
47	NULL
6/20/88	NULL
66	NULL
'	NULL
6	NULL
d	NULL
S	NULL
100	NULL
Achieved	NULL
complete	NULL
hematologic	NULL
remission	NULL
on	NULL
IFN-	NULL
alone	NULL
and	NULL
went	NULL
on	NULL
to	NULL
develop	NULL
minor	NULL
cytogenetic	NULL
remission	NULL
on	NULL
IFN	NULL
alone	NULL
48	NULL
10/10/88	NULL
27	NULL
2	NULL
d	NULL
S	NULL
100	NULL
3	NULL
Days	NULL
on	NULL
IFN	NULL
at	NULL
time	NULL
of	NULL
sample	NULL
;	NULL
ultimately	NULL
became	NULL
a	NULL
complete	NULL
hematologic	NULL
remission	NULL
on	NULL
IFN-a	NULL
alone	NULL
49	NULL
11/11/88	NULL
10	NULL
1d	NULL
S	NULL
100	NULL
Achieved	NULL
complete	NULL
hematologic	NULL
remission	NULL
on	NULL
IFN-a	NULL
and	NULL
IFN-y	NULL
50	NULL
10/18/88	NULL
27	NULL
1	NULL
yr	NULL
,	NULL
8	NULL
mo	NULL
S	NULL
100	NULL
Achieved	NULL
partial	NULL
cytogenetic	NULL
remission	NULL
on	NULL
IFN-a	NULL
(	NULL
1/88	NULL
)	NULL
51	NULL
11/11/88	NULL
26	NULL
1d	NULL
S	NULL
100	NULL
Sample	NULL
from	NULL
secondary	NULL
of	NULL
IFN	NULL
,	NULL
ultimately	NULL
developed	NULL
a	NULL
partial	NULL
cytogenetic	NULL
response	NULL
1	NULL
yr	NULL
later	NULL
52	NULL
4/20/88	NULL
100	NULL
1	NULL
yr	NULL
,	NULL
4	NULL
mo	NULL
S	NULL
100	NULL
Minor	NULL
cytogenetic	NULL
remission	NULL
after	NULL
16	NULL
mo	NULL
of	NULL
IFN-a	NULL
therapy	NULL
53	NULL
2/23/88	NULL
100	NULL
1	NULL
yr	NULL
,	NULL
1	NULL
mo	NULL
S	NULL
100	NULL
Fluctuating	NULL
minor	NULL
cytogenetic	NULL
re	NULL
sponse	NULL
on	NULL
IFN-a	NULL
and	NULL
IFN-y	NULL
after	NULL
2	NULL
yr	NULL
Abbreviation	NULL
:	NULL
S	NULL
,	NULL
sensitivity	NULL
.	NULL

complexes	NULL
formed	NULL
by	NULL
the	NULL
nuclear	NULL
proteins	NULL
before	NULL
(	NULL
Fig	NULL
4a	NULL
,	NULL
lane	NULL
3	NULL
)	NULL
and	NULL
after	NULL
(	NULL
Fig	NULL
4a	NULL
,	NULL
lane	NULL
4	NULL
)	NULL
in	NULL
vitro	NULL
exposure	NULL
to	NULL
IFN	NULL
,	NULL
this	NULL
resulted	NULL
in	NULL
an	NULL
increase	NULL
in	NULL
the	NULL
intensity	NULL
of	NULL
the	NULL
low-mobility	NULL
complex	NULL
(	NULL
band	NULL
A	NULL
in	NULL
lane	NULL
4	NULL
of	NULL
Fig	NULL
4A	NULL
)	NULL
.	NULL

The	NULL
blood	NULL
sample	NULL
of	NULL
the	NULL
same	NULL
IFN-sensitive	NULL
CML	NULL
patient	NULL
exposed	NULL
in	NULL
vivo	NULL
to	NULL
IFN-a	NULL
(	NULL
Fig	NULL
4a	NULL
,	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
before	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
and	NULL
after	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
in	NULL
vitro	NULL
exposure	NULL
to	NULL
IFN-	NULL
,	NULL
was	NULL
taken	NULL
12	NULL
to	NULL
14	NULL
hours	NULL
after	NULL
the	NULL
daily	NULL
subcutaneous	NULL
dose	NULL
of	NULL
IFN-a	NULL
.	NULL

The	NULL
serum	NULL
level	NULL
of	NULL
a	NULL
subcutaneous	NULL
dose	NULL
of	NULL
5	NULL
x	NULL
10°	NULL
U/mL	NULL
reaches	NULL
a	NULL
peak	NULL
of	NULL
250	NULL
U/mL	NULL
in	NULL
the	NULL
serum	NULL
2	NULL
hours	NULL
after	NULL
injection	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
intensity	NULL
of	NULL
the	NULL
low-mobility	NULL
complex	NULL
seen	NULL
in	NULL
lane	NULL
1	NULL
of	NULL
Fig	NULL
4a	NULL
is	NULL
less	NULL
than	NULL
that	NULL
seen	NULL
in	NULL
lanes	NULL
2	NULL
or	NULL
4	NULL
of	NULL
Fig	NULL
4a	NULL
following	NULL
in	NULL
vitro	NULL
exposure	NULL
to	NULL
1,000	NULL
U	NULL
IFN-	NULL
«	NULL
.	NULL

No	NULL
change	NULL
in	NULL
the	NULL
electrophoretic	NULL
mobility	NULL
of	NULL
nuclear	NULL
protein-DNA	NULL
complexes	NULL
was	NULL
seen	NULL
when	NULL
the	NULL
cells	NULL
of	NULL
IFN-resistant	NULL
CML	NULL
patients	NULL
were	NULL
exposed	NULL
in	NULL
vitro	NULL
to	NULL
IFN	NULL
before	NULL
nuclear	NULL
protein	NULL
isolation	NULL
(	NULL
Fig	NULL
4b	NULL
)	NULL
.	NULL

The	NULL
IFN-induced	NULL
change	NULL
in	NULL
nuclear	NULL
protein-DNA	NULL
complex	NULL
mobility	NULL
,	NULL
which	NULL
was	NULL
seen	NULL
in	NULL
cells	NULL
of	NULL
IFN-sensitive	NULL
CML	NULL
patients	NULL
,	NULL
did	NULL
not	NULL
require	NULL
de	NULL
novo	NULL
protein	NULL
synthesis	NULL
,	NULL
as	NULL
the	NULL
addition	NULL
of	NULL
cycloheximide	NULL
in	NULL
vitro	NULL
to	NULL
the	NULL
peripheral	NULL
blood	NULL
cells	NULL
of	NULL
a	NULL
CML	NULL
patient	NULL
before	NULL
the	NULL
cells	NULL
were	NULL
exposed	NULL
to	NULL
IFN	NULL
did	NULL
not	NULL
prevent	NULL
IFN-induced	NULL
changes	NULL
in	NULL
nuclear	NULL
protein	NULL
complexes	NULL
(	NULL
Fig	NULL
4¢	NULL
,	NULL
lane	NULL
3	NULL
)	NULL
.	NULL

Cytoplasmic	NULL
protein	NULL
of	NULL
chronic	NULL
myelogenous	NULL
leukemia	NULL
myeloid	NULL
cells	NULL
alters	NULL
nuclear	NULL
protein	NULL
complexes	NULL
.	NULL

If	NULL
lymphocytes	NULL
were	NULL
first	NULL
purified	NULL
from	NULL
the	NULL
myeloid	NULL
cells	NULL
present	NULL
in	NULL
CML	NULL
peripheral	NULL
blood	NULL
before	NULL
cell	NULL
lysis	NULL
and	NULL
nuclear	NULL
protein	NULL
isolation	NULL
,	NULL
a	NULL
low-mobility	NULL
complex	NULL
was	NULL
formed	NULL
between	NULL
the	NULL
IFN-inducible	NULL
transcriptional	NULL
enhancers	NULL
and	NULL
the	NULL
nuclear	NULL
proteins	NULL
of	NULL
the	NULL
lymphoid	NULL
cells	NULL
(	NULL
Fig	NULL
5	NULL
)	NULL
.	NULL

These	NULL
data	NULL
suggested	NULL
that	NULL
there	NULL
was	NULL
an	NULL
activity	NULL
in	NULL
the	NULL
peripheral	NULL
blood	NULL
myeloid	NULL
cells	NULL
of	NULL
Philadelphia	NULL
chromosome-positive	NULL
CML	NULL
cells	NULL
that	NULL
was	NULL
released	NULL
at	NULL
the	NULL
time	NULL
of	NULL
cell	NULL
lysis	NULL
and	NULL
altered	NULL
in	NULL
vitro	NULL
the	NULL
nuclear	NULL
proteins	NULL
of	NULL
lymphoid	NULL
cells	NULL
.	NULL

To	NULL
directly	NULL
test	NULL
this	NULL
hypothesis	NULL
,	NULL
we	NULL
added	NULL
a	NULL
small	NULL
amount	NULL
of	NULL
cytoplasmic	NULL
protein	NULL
of	NULL
the	NULL
peripheral	NULL
blood	NULL
myeloid	NULL
cells	NULL
of	NULL
an	NULL
IFN-sensitive	NULL
CML	NULL
patient	NULL
to	NULL
the	NULL
nuclear	NULL
proteins	NULL
of	NULL
an	NULL
established	NULL
lymphoid	NULL
cell	NULL
line	NULL
(	NULL
Daudi	NULL
)	NULL
.	NULL

We	NULL
have	NULL
previously	NULL
shown	NULL
that	NULL
the	NULL
electrophoretic	NULL
mobility	NULL
of	NULL
the	NULL
complex	NULL
formed	NULL
between	NULL
the	NULL
IFN-inducible	NULL
enhancer	NULL
and	NULL
the	NULL
nuclear	NULL
proteins	NULL
of	NULL
normal	NULL
lymphoid	NULL
cells	NULL
or	NULL
established	NULL
lymphoid	NULL
cell	NULL
lines	NULL
was	NULL
identical	NULL
.	NULL

The	NULL
addition	NULL
of	NULL
the	NULL
CML	NULL
cytoplasmic	NULL
protein	NULL
caused	NULL
a	NULL
reduction	NULL
in	NULL
the	NULL
intensity	NULL
of	NULL
the	NULL
low-mobility	NULL
complex	NULL
and	NULL
the	NULL
formation	NULL
of	NULL
a	NULL
more	NULL
rapidly	NULL
migrating	NULL
complex	NULL
(	NULL
Fig	NULL
6a	NULL
)	NULL
.	NULL

The	NULL
mobility	NULL
of	NULL
this	NULL
more	NULL
rapidly	NULL
migrating	NULL
complex	NULL
was	NULL
similar	NULL
to	NULL
that	NULL
of	NULL
the	NULL
complexes	NULL
formed	NULL
by	NULL
nuclear	NULL
proteins	NULL
of	NULL
CML	NULL
cells	NULL
.	NULL

Similar	NULL
From	NULL
www	NULL
.	NULL

bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

1124	NULL
HOWARD	NULL
ET	NULL
AL	NULL
Table	NULL
5	NULL
.	NULL

Analysis	NULL
of	NULL
Nuclear	NULL
Proteins	NULL
Extracted	NULL
From	NULL
Unfractionated	NULL
Peripheral	NULL
Blood	NULL
Cells	NULL
of	NULL
Chronic	NULL
Myelogenous	NULL
Leukemia	NULL
Patients	NULL
Who	NULL
Are	NULL
Partial	NULL
Cytogenetic	NULL
Responders	NULL
:	NULL
Samples	NULL
Collected	NULL
While	NULL
on	NULL
IFN	NULL
Time	NULL
Elapsed	NULL
%	NULL
Low-Mobility	NULL
Between	NULL
Initiation	NULL
Clinical	NULL
Patient	NULL
Complex	NULL
of	NULL
Therapy	NULL
and	NULL
Sensitivity	NULL
%	NULL
No	NULL
.	NULL

Date	NULL
(	NULL
Band	NULL
A	NULL
)	NULL
Sample	NULL
Collection	NULL
to	NULL
IFN	NULL
Ph+	NULL
Comments	NULL
Partial	NULL
cytogenetic	NULL
responders	NULL
7	NULL
10/11/88	NULL
98	NULL
3	NULL
mo	NULL
76	NULL
WBC	NULL
decreased	NULL
from	NULL
70,000	NULL
to	NULL
3,000	NULL
in	NULL
3	NULL
mo	NULL
on	NULL
IFN-	NULL
alone	NULL
;	NULL
went	NULL
on	NULL
to	NULL
develop	NULL
complete	NULL
cytogenetic	NULL
remission	NULL
54	NULL
10/24/88	NULL
100	NULL
9	NULL
mo	NULL
88	NULL
Achieved	NULL
complete	NULL
hematologic	NULL
remission	NULL
at	NULL
time	NULL
of	NULL
this	NULL
sample	NULL
on	NULL
IFN-a	NULL
alone	NULL
and	NULL
went	NULL
on	NULL
to	NULL
develop	NULL
partial	NULL
cytogenetic	NULL
remission	NULL
several	NULL
months	NULL
later	NULL
55	NULL
9/18/89	NULL
100	NULL
5	NULL
yr	NULL
,	NULL
9	NULL
mo	NULL
10	NULL
{	NULL
clonal	NULL
evolution	NULL
}	NULL
Initial	NULL
CHR	NULL
on	NULL
IFN-a	NULL
lasted	NULL
54	NULL
mo	NULL
,	NULL
clonal	NULL
evolution	NULL
occurred	NULL
and	NULL
was	NULL
treated	NULL
successfully	NULL
to	NULL
a	NULL
cytogenetic	NULL
remission	NULL
with	NULL
IFN-a	NULL
and	NULL
ara-C	NULL
56	NULL
3/8/89	NULL
69	NULL
10	NULL
mo	NULL
30	NULL
Went	NULL
into	NULL
complete	NULL
cytogenetic	NULL
remission	NULL
on	NULL
IFN-	NULL
;	NULL
sample	NULL
from	NULL
day	NULL
3	NULL
of	NULL
IFN	NULL
was	NULL
negative	NULL
for	NULL
the	NULL
low-mobility	NULL
complex	NULL
57	NULL
4/29/88	NULL
45	NULL
1	NULL
yr	NULL
,	NULL
6	NULL
mo	NULL
96	NULL
In	NULL
partial	NULL
hematologic	NULL
remission	NULL
(	NULL
WBC	NULL
<	NULL
10,000	NULL
but	NULL
immature	NULL
forms	NULL
present	NULL
with	NULL
palpable	NULL
spleen	NULL
)	NULL
58	NULL
4/14/88	NULL
100	NULL
8	NULL
mo	NULL
50	NULL
16	NULL
mo	NULL
on	NULL
IFN-a	NULL
,	NULL
and	NULL
-y	NULL
led	NULL
to	NULL
partial	NULL
cytogenetic	NULL
remission	NULL
59	NULL
4/1/88	NULL
100	NULL
1	NULL
yr	NULL
,	NULL
9	NULL
mo	NULL
75	NULL
Presented	NULL
with	NULL
clonal	NULL
evolution	NULL
which	NULL
was	NULL
suppressed	NULL
along	NULL
with	NULL
25	NULL
%	NULL
of	NULL
the	NULL
Ph+	NULL
cells	NULL
on	NULL
IFN-	NULL
and	NULL
-y	NULL
over	NULL
2	NULL
years	NULL
60	NULL
4/7/88	NULL
100	NULL
1	NULL
yr	NULL
,	NULL
3	NULL
d	NULL
76	NULL
Partial	NULL
cytogenetic	NULL
remission	NULL
after	NULL
1	NULL
year	NULL
of	NULL
IFN-a	NULL
therapy	NULL
61	NULL
4/18/88	NULL
100	NULL
1	NULL
yr	NULL
,	NULL
2	NULL
mo	NULL
80	NULL
Developed	NULL
partial	NULL
cytogenetic	NULL
remission	NULL
14	NULL
mo	NULL
after	NULL
start	NULL
of	NULL
IFN	NULL
therapy	NULL
62	NULL
5/12/88	NULL
100	NULL
2	NULL
yr	NULL
90	NULL
IFN-a	NULL
and	NULL
-y	NULL
for	NULL
2.0	NULL
yr	NULL
led	NULL
to	NULL
minor	NULL
cytogenetic	NULL
remission	NULL
63	NULL
2/4/88	NULL
38	NULL
3	NULL
yr	NULL
,	NULL
4	NULL
mo	NULL
75	NULL
2.5	NULL
yr	NULL
of	NULL
IFN-y	NULL
induced	NULL
almost	NULL
complete	NULL
cytogenetic	NULL
remission	NULL
3	NULL
yr	NULL
after	NULL
diagnosis	NULL
64	NULL
2/9/88	NULL
0	NULL
3	NULL
mo	NULL
45	NULL
Treated	NULL
with	NULL
IFN-a	NULL
for	NULL
3	NULL
mo	NULL
during	NULL
which	NULL
she	NULL
developed	NULL
partial	NULL
cytogenetic	NULL
remission	NULL
Abbreviations	NULL
:	NULL
S	NULL
,	NULL
sensitivity	NULL
;	NULL
WBC	NULL
,	NULL
white	NULL
blood	NULL
cell	NULL
count	NULL
.	NULL

changes	NULL
occurred	NULL
when	NULL
the	NULL
peripheral	NULL
blood	NULL
cells	NULL
of	NULL
an	NULL
IFN-resistant	NULL
CML	NULL
patient	NULL
were	NULL
used	NULL
to	NULL
generate	NULL
a	NULL
cytoplasmic	NULL
extract	NULL
(	NULL
Fig	NULL
6b	NULL
)	NULL
.	NULL

However	NULL
,	NULL
almost	NULL
no	NULL
change	NULL
was	NULL
seen	NULL
when	NULL
the	NULL
cytoplasmic	NULL
proteins	NULL
of	NULL
the	NULL
peripheral	NULL
blood	NULL
cells	NULL
of	NULL
a	NULL
normal	NULL
individual	NULL
were	NULL
used	NULL
to	NULL
generate	NULL
the	NULL
cytoplasmic	NULL
extract	NULL
or	NULL
when	NULL
the	NULL
mature	NULL
marrow	NULL
cells	NULL
(	NULL
bands	NULL
and	NULL
neutrophils	NULL
)	NULL
of	NULL
a	NULL
normal	NULL
individual	NULL
were	NULL
used	NULL
to	NULL
generate	NULL
the	NULL
cytoplasmic	NULL
extracts	NULL
(	NULL
Fig	NULL
6c	NULL
,	NULL
lane	NULL
3	NULL
)	NULL
.	NULL

The	NULL
cytoplasmic	NULL
proteins	NULL
of	NULL
the	NULL
immature	NULL
marrow	NULL
myeloid	NULL
cells	NULL
(	NULL
blasts	NULL
and	NULL
promyelocytes	NULL
)	NULL
generated	NULL
only	NULL
a	NULL
small	NULL
amount	NULL
of	NULL
change	NULL
on	NULL
the	NULL
nuclear	NULL
protein	NULL
complexes	NULL
(	NULL
Fig	NULL
6¢	NULL
,	NULL
lane	NULL
2	NULL
)	NULL
.	NULL

These	NULL
in	NULL
vitro	NULL
experiments	NULL
were	NULL
performed	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
high	NULL
concen-	NULL
trations	NULL
of	NULL
the	NULL
protease	NULL
inhibitors	NULL
phenylmethylsulfonyl	NULL
fluo-ride	NULL
,	NULL
aprotinin	NULL
,	NULL
and	NULL
benzamide	NULL
.	NULL

The	NULL
change	NULL
induced	NULL
in	NULL
the	NULL
mobility	NULL
of	NULL
the	NULL
nuclear	NULL
protein	NULL
complexes	NULL
by	NULL
the	NULL
CML	NULL
cell	NULL
lysate	NULL
was	NULL
temperature	NULL
(	NULL
oc-curred	NULL
at	NULL
22°C	NULL
,	NULL
but	NULL
not	NULL
at	NULL
5°C	NULL
)	NULL
and	NULL
time	NULL
(	NULL
barely	NULL
detectable	NULL
at	NULL
5	NULL
minutes	NULL
,	NULL
but	NULL
complete	NULL
by	NULL
1	NULL
hour	NULL
)	NULL
dependent	NULL
.	NULL

This	NULL
activity	NULL
was	NULL
localized	NULL
predominantly	NULL
in	NULL
the	NULL
cytoplasm	NULL
of	NULL
CML	NULL
myeloid	NULL
cells	NULL
.	NULL

The	NULL
levels	NULL
of	NULL
this	NULL
activity	NULL
in	NULL
the	NULL
peripheral	NULL
blood	NULL
myeloid	NULL
cells	NULL
of	NULL
normal	NULL
individuals	NULL
were	NULL
almost	NULL
undetectable	NULL
,	NULL
although	NULL
it	NULL
was	NULL
present	NULL
in	NULL
blasts	NULL
and	NULL
promyelocytes	NULL
isolated	NULL
from	NULL
the	NULL
marrow	NULL
of	NULL
normal	NULL
individu-als	NULL
.	NULL

The	NULL
addition	NULL
of	NULL
orthovanadate	NULL
(	NULL
0.01	NULL
to	NULL
0.1	NULL
mmol/L	NULL
)	NULL
,	NULL
From	NULL
www	NULL
.	NULL

bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

INTERFERON	NULL
AND	NULL
NUCLEAR	NULL
PROTEINS	NULL
IN	NULL
CML	NULL
1125	NULL
Table	NULL
6	NULL
.	NULL

Analysis	NULL
of	NULL
Nuclear	NULL
Proteins	NULL
Isolated	NULL
From	NULL
CML	NULL
Patients	NULL
Who	NULL
Are	NULL
Complete	NULL
Cytogenetic	NULL
Responders	NULL
:	NULL
Samples	NULL
Collected	NULL
White	NULL
on	NULL
Interferon	NULL
Time	NULL
Elapsed	NULL
%	NULL
Low-Mobility	NULL
Between	NULL
Initiation	NULL
Clinical	NULL
Patient	NULL
Complex	NULL
of	NULL
Therapy	NULL
and	NULL
Sensitivity	NULL
%	NULL
No	NULL
.	NULL

Date	NULL
(	NULL
Band	NULL
A	NULL
)	NULL
Sample	NULL
Collection	NULL
to	NULL
IFN	NULL
Ph+	NULL
Comments	NULL
65	NULL
5/2/88	NULL
88	NULL
11d	NULL
S	NULL
0	NULL
100	NULL
%	NULL
Ph-	NULL
cells	NULL
after	NULL
18	NULL
mo	NULL
IFN-a	NULL
;	NULL
eventually	NULL
started	NULL
to	NULL
loose	NULL
cytogenetic	NULL
remission	NULL
66	NULL
5/18/88	NULL
100	NULL
1	NULL
yr	NULL
,	NULL
1	NULL
mo	NULL
S	NULL
0	NULL
100	NULL
%	NULL
Ph-	NULL
cells	NULL
after	NULL
5	NULL
mo	NULL
of	NULL
IFN-and	NULL
~y	NULL
67	NULL
5/19/88	NULL
75	NULL
6	NULL
yr	NULL
,	NULL
2	NULL
mo	NULL
S	NULL
0	NULL
100	NULL
%	NULL
Ph-	NULL
cells	NULL
after	NULL
45	NULL
mo	NULL
IFN-a	NULL
68	NULL
6/16/88	NULL
100	NULL
5	NULL
yr	NULL
,	NULL
3	NULL
mo	NULL
S	NULL
0	NULL
100	NULL
%	NULL
Ph-	NULL
cells	NULL
after	NULL
5	NULL
yr	NULL
and	NULL
3	NULL
mo	NULL
IFN	NULL
69	NULL
10/24/88	NULL
100	NULL
11	NULL
mo	NULL
S	NULL
0	NULL
100	NULL
%	NULL
Ph-	NULL
after	NULL
21	NULL
mo	NULL
IFN-a	NULL
and	NULL
-Y	NULL
70	NULL
11/30/88	NULL
82	NULL
6	NULL
yr	NULL
,	NULL
3	NULL
mo	NULL
S	NULL
0	NULL
100	NULL
%	NULL
Ph-	NULL
cells	NULL
after	NULL
45	NULL
mo	NULL
IFN-a	NULL
71	NULL
11/29/88	NULL
100	NULL
4	NULL
yr	NULL
,	NULL
2	NULL
mo	NULL
S	NULL
0	NULL
100	NULL
%	NULL
Ph-	NULL
after	NULL
11	NULL
mo	NULL
IFN-a	NULL
Abbreviation	NULL
:	NULL
S	NULL
,	NULL
sensitivity	NULL
.	NULL

Table	NULL
7	NULL
.	NULL

Analysis	NULL
of	NULL
Nuclear	NULL
Proteins	NULL
Extracted	NULL
From	NULL
Unfractionated	NULL
Peripheral	NULL
Blood	NULL
Cells	NULL
of	NULL
CML	NULL
Patients	NULL
Resistant	NULL
to	NULL
Interferon	NULL
:	NULL
Sample	NULL
Collected	NULL
While	NULL
on	NULL
Interferon	NULL
Time	NULL
Elapsed	NULL
%	NULL
Low-Mobility	NULL
Between	NULL
Initiation	NULL
Clinical	NULL
Patient	NULL
Complex	NULL
of	NULL
Therapy	NULL
and	NULL
Sensitivity	NULL
%	NULL
No	NULL
.	NULL

Date	NULL
(	NULL
Band	NULL
A	NULL
)	NULL
Sample	NULL
Collection	NULL
to	NULL
IFN	NULL
Ph+	NULL
Comments	NULL
17	NULL
2/23/89	NULL
0	NULL
3	NULL
mo	NULL
1°R	NULL
100	NULL
Primary	NULL
resistance	NULL
18	NULL
9/21/88	NULL
0	NULL
1	NULL
yr	NULL
,	NULL
5	NULL
mo	NULL
1°R	NULL
84	NULL
Primary	NULL
resistance	NULL
(	NULL
evolved	NULL
into	NULL
accelerated	NULL
phase	NULL
in	NULL
IFN-q	NULL
)	NULL
19	NULL
6/14/88	NULL
0	NULL
1	NULL
d	NULL
1°R	NULL
100	NULL
Primary	NULL
resistance	NULL
21	NULL
5/31/88	NULL
1	NULL
5	NULL
mo	NULL
1°R	NULL
100	NULL
Initially	NULL
primary	NULL
resistance	NULL
22	NULL
10/24/88	NULL
0	NULL
1	NULL
yr	NULL
,	NULL
2	NULL
mo	NULL
1°R	NULL
100	NULL
Primary	NULL
resistance	NULL
26	NULL
5/9/88	NULL
0	NULL
1	NULL
yr	NULL
,	NULL
10	NULL
mo	NULL
1°R	NULL
100	NULL
Primary	NULL
resistance	NULL
28	NULL
6/2/88	NULL
0	NULL
4	NULL
yr	NULL
,	NULL
6	NULL
mo	NULL
2°R	NULL
100	NULL
CHR	NULL
on	NULL
IFN-a	NULL
then	NULL
acquired	NULL
secondary	NULL
resistance	NULL
with	NULL
acceleration	NULL
;	NULL
treated	NULL
with	NULL
ara-C/IFN	NULL
31	NULL
4/8/88	NULL
0	NULL
1	NULL
yr	NULL
,	NULL
8	NULL
mo	NULL
2°R	NULL
100	NULL
Resistance	NULL
to	NULL
IFN-a	NULL
and	NULL
~y	NULL
34	NULL
11/3/88	NULL
0	NULL
5	NULL
yr	NULL
2°R	NULL
100	NULL
Secondary	NULL
resistance	NULL
(	NULL
clonal	NULL
evolution	NULL
}	NULL
35	NULL
5/13/88	NULL
0	NULL
4	NULL
yr	NULL
,	NULL
5	NULL
mo	NULL
2°R	NULL
100	NULL
Achieved	NULL
CHR	NULL
on	NULL
IFN-	NULL
,	NULL
but	NULL
was	NULL
taken	NULL
off	NULL
due	NULL
to	NULL
bone	NULL
pain	NULL
;	NULL
sample	NULL
taken	NULL
3	NULL
yr	NULL
later	NULL
24	NULL
hr	NULL
after	NULL
starting	NULL
IFN	NULL
was	NULL
resistant	NULL
to	NULL
IFN/ara-C	NULL
72	NULL
4/5/88	NULL
0	NULL
1	NULL
yr	NULL
,	NULL
5	NULL
mo	NULL
1°R	NULL
100	NULL
Primary	NULL
resistance	NULL
to	NULL
IFN-a	NULL
and	NULL
-y	NULL
(	NULL
clonal	NULL
evolution	NULL
)	NULL
73	NULL
12/5/88	NULL
0	NULL
5	NULL
yr	NULL
2°R	NULL
100	NULL
Secondary	NULL
resistance	NULL
2	NULL
yr	NULL
after	NULL
initial	NULL
partial	NULL
cytogenetic	NULL
remission	NULL
on	NULL
IFN	NULL
74	NULL
10/24/88	NULL
0	NULL
5	NULL
yr	NULL
2°R	NULL
100	NULL
Secondary	NULL
resistance	NULL
after	NULL
partial	NULL
cytogenetic	NULL
response	NULL
to	NULL
IFN	NULL
Abbreviations	NULL
:	NULL
CHR	NULL
,	NULL
complete	NULL
hematological	NULL
remission	NULL
;	NULL
1°R	NULL
,	NULL
primary	NULL
resistance	NULL
;	NULL
2°R	NULL
,	NULL
secondary	NULL
resistance	NULL
;	NULL
INE	NULL
,	NULL
inevaluable	NULL
;	NULL
Ph	NULL
,	NULL
Philadelphia	NULL
chromosome	NULL
;	NULL
DOAP	NULL
,	NULL
daunomycin	NULL
,	NULL
oncovin	NULL
,	NULL
ara-C	NULL
,	NULL
and	NULL
prednisone	NULL
.	NULL

From	NULL
www	NULL
.	NULL

bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

1126	NULL
HOWARD	NULL
ET	NULL
AL	NULL
a	NULL
b	NULL
Fig	NULL
4	NULL
.	NULL

(	NULL
a	NULL
)	NULL
In	NULL
vitro	NULL
effect	NULL
of	NULL
IFN-a	NULL
on	NULL
nuclear	NULL
proteins	NULL
of	NULL
IFN-sensitive	NULL
CML	NULL
patient	NULL
.	NULL

Gel	NULL
mobility-shift	NULL
analysis	NULL
of	NULL
complexes	NULL
formed	NULL
between	NULL
the	NULL
2,5-0AS	NULL
transcriptional	NULL
enhancer	NULL
and	NULL
the	NULL
nuclear	NULL
proteins	NULL
of	NULL
peripheral	NULL
blood	NULL
cells	NULL
of	NULL
IFN-sensitive	NULL
early	NULL
chronic	NULL
phase	NULL
CML	NULL
patients	NULL
.	NULL

Lanes	NULL
1	NULL
and	NULL
2	NULL
:	NULL
peripheral	NULL
blood	NULL
sample	NULL
collected	NULL
while	NULL
the	NULL
patient	NULL
was	NULL
receiving	NULL
daily	NULL
subcutaneous	NULL
interferon	NULL
.	NULL

Lanes	NULL
3	NULL
and	NULL
4	NULL
:	NULL
Sample	NULL
collected	NULL
while	NULL
patient	NULL
was	NULL
not	NULL
receiving	NULL
daily	NULL
subcutaneous	NULL
interferon	NULL
.	NULL

Lanes	NULL
1	NULL
and	NULL
3	NULL
:	NULL
before	NULL
in	NULL
vitro	NULL
exposure	NULL
to	NULL
IFN-a	NULL
.	NULL

Lanes	NULL
2	NULL
and	NULL
4	NULL
:	NULL
after	NULL
in	NULL
vitro	NULL
exposure	NULL
to	NULL
1,000	NULL
U/ml	NULL
.	NULL

IFN-a	NULL
for	NULL
1	NULL
hour	NULL
at	NULL
37°C	NULL
.	NULL

The	NULL
gel	NULL
was	NULL
run	NULL
at	NULL
5	NULL
V/cm	NULL
for	NULL
12	NULL
hours	NULL
.	NULL

The	NULL
low-mobility	NULL
complex	NULL
is	NULL
band	NULL
A	NULL
and	NULL
the	NULL
high-mobility	NULL
complex	NULL
is	NULL
band	NULL
B	NULL
.	NULL

The	NULL
area	NULL
at	NULL
the	NULL
bottom	NULL
of	NULL
each	NULL
lane	NULL
contains	NULL
the	NULL
unbound	NULL
probe	NULL
.	NULL

(	NULL
b	NULL
)	NULL
In	NULL
vitro	NULL
effect	NULL
of	NULL
IFN-a	NULL
on	NULL
nuclear	NULL
proteins	NULL
of	NULL
IFN-resistant	NULL
CML	NULL
patient	NULL
.	NULL

Gel	NULL
mobility-shift	NULL
analysis	NULL
of	NULL
complexes	NULL
formed	NULL
between	NULL
the	NULL
2,5-O0AS	NULL
transcriptional	NULL
h	NULL
and	NULL
the	NULL
lear	NULL
proteins	NULL
isolated	NULL
from	NULL
the	NULL
peripheral	NULL
blood	NULL
cells	NULL
of	NULL
an	NULL
IFN-resi	NULL
CML	NULL
pati	NULL
not	NULL
receiving	NULL
daily	NULL
IFN	NULL
and	NULL
before	NULL
in	NULL
vitro	NULL
exposure	NULL
to	NULL
IFN-a	NULL
(	NULL
lane	NULL
on	NULL
left	NULL
)	NULL
,	NULL
or	NULL
from	NULL
the	NULL
peripheral	NULL
blood	NULL
cells	NULL
collected	NULL
while	NULL
the	NULL
patient	NULL
was	NULL
not	NULL
receiving	NULL
daily	NULL
subcutaneous	NULL
injection	NULL
of	NULL
IFN-a	NULL
but	NULL
after	NULL
in	NULL
vitro	NULL
exposure	NULL
to	NULL
1,000	NULL
U/mL	NULL
of	NULL
IFN-a	NULL
for	NULL
1	NULL
hour	NULL
at	NULL
37°C	NULL
(	NULL
lane	NULL
on	NULL
right	NULL
)	NULL
.	NULL

The	NULL
gel	NULL
was	NULL
run	NULL
at	NULL
5	NULL
V/cm	NULL
for	NULL
12	NULL
hours	NULL
.	NULL

The	NULL
position	NULL
of	NULL
the	NULL
low-mobility	NULL
complex	NULL
is	NULL
indicated	NULL
by	NULL
``	NULL
'	NULL
A	NULL
'	NULL
``	NULL
and	NULL
the	NULL
position	NULL
of	NULL
the	NULL
high-mobility	NULL
complex	NULL
is	NULL
indicated	NULL
by	NULL
``	NULL
B	NULL
.	NULL
``	NULL

The	NULL
unbound	NULL
probe	NULL
was	NULL
run	NULL
off	NULL
the	NULL
end	NULL
of	NULL
the	NULL
gel	NULL
in	NULL
this	NULL
case	NULL
.	NULL

(	NULL
c	NULL
)	NULL
Testing	NULL
of	NULL
cycloheximide	NULL
sensitivity	NULL
of	NULL
IFN-induced	NULL
change	NULL
in	NULL
electrophoretic	NULL
mobility	NULL
of	NULL
complexes	NULL
formed	NULL
between	NULL
the	NULL
IFN-inducible	NULL
transcriptional	NULL
enh	NULL
and	NULL
I	NULL
proteins	NULL
from	NULL
CML	NULL
cell	NULL
lines	NULL
.	NULL

Gel	NULL
mobility-shift	NULL
analysis	NULL
of	NULL
complexes	NULL
formed	NULL
between	NULL
the	NULL
2,5-OAS	NULL
transcriptional	NULL
enhancer	NULL
and	NULL
the	NULL
nuclear	NULL
proteins	NULL
of	NULL
the	NULL
myeloid	NULL
cells	NULL
of	NULL
an	NULL
IFN-sensitive	NULL
CML	NULL
patient	NULL
.	NULL

Nuclear	NULL
proteins	NULL
were	NULL
isolated	NULL
before	NULL
exposure	NULL
to	NULL
IFN-a	NULL
(	NULL
lane	NULL
1	NULL
}	NULL
,	NULL
after	NULL
in	NULL
vitro	NULL
exposure	NULL
to	NULL
1,000	NULL
U/ml	NULL
.	NULL

of	NULL
IFN-a	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
,	NULL
or	NULL
after	NULL
exposure	NULL
to	NULL
1,000	NULL
U/ml	NULL
.	NULL

of	NULL
IFN-a	NULL
following	NULL
pretr	NULL
with	NULL
10	NULL
1/L	NULL
cycloheximide	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
exposed	NULL
in	NULL
vitro	NULL
to	NULL
1,000	NULL
U/ml	NULL
IFN-a	NULL
at	NULL
37°C	NULL
for	NULL
1	NULL
hour	NULL
.	NULL

The	NULL
gel	NULL
was	NULL
run	NULL
for	NULL
5	NULL
V/cm	NULL
for	NULL
12	NULL
hours	NULL
.	NULL

The	NULL
effect	NULL
of	NULL
IFN-a	NULL
on	NULL
the	NULL
mobility	NULL
of	NULL
nuclear	NULL
protein	NULL
complexes	NULL
is	NULL
not	NULL
inhibitable	NULL
by	NULL
pretreatment	NULL
with	NULL
cycloheximide	NULL
.	NULL

From	NULL
www	NULL
.	NULL

bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

INTERFERON	NULL
AND	NULL
NUCLEAR	NULL
PROTEINS	NULL
IN	NULL
CML	NULL
Fig	NULL
5	NULL
.	NULL

Complexes	NULL
formed	NULL
between	NULL
the	NULL
2,5-0AS	NULL
oligonucleotide	NULL
and	NULL
nuclear	NULL
proteins	NULL
of	NULL
purified	NULL
lymphocytes	NULL
or	NULL
purified	NULL
myeloid	NULL
cells	NULL
from	NULL
CML	NULL
peripheral	NULL
blood	NULL
.	NULL

Lymphoid	NULL
peripheral	NULL
blood	NULL
cells	NULL
were	NULL
separated	NULL
from	NULL
myeloid	NULL
peripheral	NULL
blood	NULL
cells	NULL
before	NULL
cell	NULL
lysis	NULL
for	NULL
extraction	NULL
of	NULL
nuclear	NULL
proteins	NULL
.	NULL

Lane	NULL
1	NULL
:	NULL
complex	NULL
formed	NULL
between	NULL
nuclear	NULL
proteins	NULL
from	NULL
the	NULL
``	NULL
myeloid	NULL
``	NULL
fraction	NULL
of	NULL
peripheral	NULL
blood	NULL
cells	NULL
of	NULL
an	NULL
IFN-sensitive	NULL
CML	NULL
patient	NULL
and	NULL
the	NULL
IFN-inducible	NULL
transcriptional	NULL
enhancer	NULL
.	NULL

Lane	NULL
2	NULL
:	NULL
complex	NULL
formed	NULL
between	NULL
nuclear	NULL
proteins	NULL
from	NULL
the	NULL
``	NULL
lymphoid	NULL
``	NULL
fraction	NULL
of	NULL
peripheral	NULL
blood	NULL
cells	NULL
of	NULL
an	NULL
IFN-sensitive	NULL
CML	NULL
patient	NULL
and	NULL
the	NULL
2,5-0AS	NULL
oligonucleotide	NULL
.	NULL

The	NULL
gel	NULL
was	NULL
run	NULL
at	NULL
5	NULL
V/cm	NULL
for	NULL
12	NULL
hours	NULL
.	NULL

Band	NULL
A	NULL
is	NULL
the	NULL
low-mobility	NULL
complex	NULL
and	NULL
band	NULL
B	NULL
is	NULL
the	NULL
high-mobility	NULL
complex	NULL
.	NULL

The	NULL
area	NULL
at	NULL
the	NULL
bottom	NULL
of	NULL
each	NULL
lane	NULL
shows	NULL
the	NULL
unbound	NULL
probe	NULL
.	NULL

which	NULL
is	NULL
a	NULL
phosphatase	NULL
inhibitor	NULL
,	NULL
``	NULL
to	NULL
CML	NULL
cells	NULL
before	NULL
isolation	NULL
of	NULL
cytoplasmic	NULL
proteins	NULL
or	NULL
to	NULL
the	NULL
cytoplasmic	NULL
proteins	NULL
themselves	NULL
,	NULL
diminished	NULL
the	NULL
effect	NULL
of	NULL
the	NULL
cytoplasmic	NULL
proteins	NULL
on	NULL
the	NULL
electrophoretic	NULL
mobility	NULL
of	NULL
nuclear	NULL
protein	NULL
complexes	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Finally	NULL
,	NULL
IFN	NULL
treatment	NULL
of	NULL
the	NULL
cells	NULL
of	NULL
IFN-sensitive	NULL
patients	NULL
appeared	NULL
to	NULL
diminish	NULL
the	NULL
effect	NULL
of	NULL
the	NULL
CML	NULL
cytoplasmic	NULL
protein	NULL
on	NULL
the	NULL
electrophoretic	NULL
mobility	NULL
of	NULL
these	NULL
nuclear	NULL
protein-DNA	NULL
complexes	NULL
(	NULL
Fig	NULL
6a	NULL
,	NULL
lane	NULL
S	NULL
)	NULL
.	NULL

Exposure	NULL
of	NULL
the	NULL
cells	NULL
of	NULL
IFN-resistant	NULL
CML	NULL
patients	NULL
to	NULL
IFN-a	NULL
,	NULL
did	NULL
not	NULL
diminish	NULL
the	NULL
effect	NULL
of	NULL
the	NULL
cytoplasmic	NULL
protein	NULL
on	NULL
electrophoretic	NULL
mobility	NULL
of	NULL
IFN-inducible	NULL
complexes	NULL
,	NULL
as	NULL
shown	NULL
in	NULL
lane	NULL
3	NULL
of	NULL
Fig	NULL
6b	NULL
.	NULL

This	NULL
data	NULL
suggested	NULL
that	NULL
there	NULL
was	NULL
an	NULL
activity	NULL
in	NULL
the	NULL
peripheral	NULL
blood	NULL
myeloid	NULL
cells	NULL
of	NULL
CML	NULL
patients	NULL
,	NULL
which	NULL
is	NULL
not	NULL
present	NULL
in	NULL
normal	NULL
peripheral	NULL
blood	NULL
myeloid	NULL
cells	NULL
,	NULL
that	NULL
altered	NULL
the	NULL
electrophoretic	NULL
mobility	NULL
of	NULL
complexes	NULL
between	NULL
transcriptional	NULL
enhancers	NULL
and	NULL
nuclear	NULL
proteins	NULL
.	NULL

We	NULL
then	NULL
tested	NULL
in	NULL
vitro	NULL
the	NULL
effect	NULL
of	NULL
purified	NULL
enzymes	NULL
that	NULL
might	NULL
account	NULL
for	NULL
this	NULL
effect	NULL
of	NULL
CML	NULL
cellular	NULL
proteins	NULL
on	NULL
nuclear	NULL
proteins	NULL
.	NULL

When	NULL
we	NULL
added	NULL
an	NULL
acid	NULL
phosphatase	NULL
to	NULL
the	NULL
nuclear	NULL
proteins	NULL
from	NULL
the	NULL
Daudi	NULL
cell	NULL
line	NULL
,	NULL
the	NULL
intensity	NULL
of	NULL
the	NULL
low-mobility	NULL
complex	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
decreased	NULL
and	NULL
complexes	NULL
of	NULL
more	NULL
rapid	NULL
mobility	NULL
(	NULL
lanes	NULL
2	NULL
and	NULL
3	NULL
)	NULL
were	NULL
generated	NULL
,	NULL
as	NULL
shown	NULL
in	NULL
Fig	NULL
7	NULL
.	NULL

As	NULL
shown	NULL
by	NULL
a	NULL
comparison	NULL
of	NULL
lanes	NULL
2	NULL
,	NULL
3	NULL
,	NULL
and	NULL
4	NULL
,	NULL
the	NULL
electrophoretic	NULL
mobility	NULL
of	NULL
the	NULL
acid	NULL
phosphatase-treated	NULL
nuclear	NULL
proteins	NULL
was	NULL
higher	NULL
than	NULL
that	NULL
formed	NULL
by	NULL
Daudi	NULL
1127	NULL
nuclear	NULL
proteins	NULL
before	NULL
phosphatase	NULL
exposure	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
effect	NULL
of	NULL
acid	NULL
phosphatase	NULL
is	NULL
to	NULL
generate	NULL
complexes	NULL
that	NULL
have	NULL
mobilities	NULL
similar	NULL
to	NULL
those	NULL
seen	NULL
with	NULL
nuclear	NULL
proteins	NULL
from	NULL
normal	NULL
lymphoid	NULL
or	NULL
Daudi	NULL
cells	NULL
following	NULL
exposure	NULL
to	NULL
the	NULL
cytoplasmic	NULL
proteins	NULL
of	NULL
CML	NULL
cells	NULL
(	NULL
Fig	NULL
6	NULL
)	NULL
.	NULL

The	NULL
electrophoretic	NULL
mobility	NULL
of	NULL
the	NULL
high-mobility	NULL
complexes	NULL
generated	NULL
in	NULL
lanes	NULL
2	NULL
and	NULL
3	NULL
by	NULL
exposure	NULL
to	NULL
phosphatase	NULL
is	NULL
slightly	NULL
less	NULL
than	NULL
that	NULL
of	NULL
the	NULL
high-mobility	NULL
complex	NULL
present	NULL
in	NULL
the	NULL
CML	NULL
cell	NULL
line	NULL
EM-2	NULL
(	NULL
Fig	NULL
7	NULL
,	NULL
lane	NULL
4	NULL
)	NULL
.	NULL

This	NULL
may	NULL
reflect	NULL
the	NULL
degree	NULL
to	NULL
which	NULL
the	NULL
potato	NULL
phosphatase	NULL
can	NULL
dephosphorylate	NULL
the	NULL
nuclear	NULL
proteins	NULL
of	NULL
the	NULL
Daudi	NULL
cells	NULL
in	NULL
vitro	NULL
.	NULL

These	NULL
data	NULL
suggest	NULL
that	NULL
the	NULL
cytoplasm	NULL
of	NULL
CML	NULL
cells	NULL
contains	NULL
a	NULL
phosphatase	NULL
that	NULL
alters	NULL
the	NULL
mobility	NULL
of	NULL
the	NULL
complexes	NULL
formed	NULL
between	NULL
nuclear	NULL
proteins	NULL
and	NULL
IFN-inducible	NULL
transcriptional	NULL
enhancers	NULL
,	NULL
and	NULL
that	NULL
IFN-a	NULL
reverses	NULL
these	NULL
changes	NULL
through	NULL
a	NULL
posttranslational	NULL
effect	NULL
in	NULL
the	NULL
IFN-sensitive	NULL
Philadelphia	NULL
chromosome-positive	NULL
CML	NULL
myeloid	NULL
cell	NULL
.	NULL

DISCUSSION	NULL
Our	NULL
studies	NULL
show	NULL
that	NULL
the	NULL
cytoplasmic	NULL
proteins	NULL
of	NULL
CML	NULL
peripheral	NULL
blood	NULL
myeloid	NULL
cells	NULL
induced	NULL
a	NULL
change	NULL
in	NULL
the	NULL
electrophoretic	NULL
mobility	NULL
of	NULL
complexes	NULL
formed	NULL
between	NULL
the	NULL
transcriptional	NULL
enhancer	NULL
sequences	NULL
of	NULL
the	NULL
IFN-inducible	NULL
genes	NULL
6-16	NULL
,	NULL
9-27	NULL
,	NULL
beta-2	NULL
microglobulin	NULL
,	NULL
and	NULL
2,5-OAS	NULL
and	NULL
the	NULL
nuclear	NULL
proteins	NULL
of	NULL
hematopoietic	NULL
cells	NULL
.	NULL

The	NULL
CML	NULL
cytoplasmic	NULL
proteins	NULL
converted	NULL
the	NULL
electrophoretic	NULL
mobility	NULL
of	NULL
nuclear	NULL
protein-DNA	NULL
complexes	NULL
from	NULL
low	NULL
to	NULL
high	NULL
mobility	NULL
.	NULL

The	NULL
cytoplasmic	NULL
proteins	NULL
of	NULL
the	NULL
mature	NULL
myeloid	NULL
peripheral	NULL
blood	NULL
cells	NULL
of	NULL
normal	NULL
individuals	NULL
had	NULL
little	NULL
or	NULL
no	NULL
effect	NULL
on	NULL
the	NULL
mobility	NULL
of	NULL
these	NULL
complexes	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
presence	NULL
of	NULL
proteins	NULL
(	NULL
which	NULL
alter	NULL
nuclear	NULL
protein-DNA	NULL
complexes	NULL
)	NULL
in	NULL
the	NULL
cytoplasm	NULL
of	NULL
CML	NULL
cells	NULL
may	NULL
account	NULL
for	NULL
the	NULL
differences	NULL
seen	NULL
in	NULL
the	NULL
electrophoretic	NULL
mobility	NULL
of	NULL
the	NULL
complexes	NULL
formed	NULL
between	NULL
transcriptional	NULL
enhancers	NULL
and	NULL
the	NULL
nuclear	NULL
proteins	NULL
of	NULL
normal	NULL
versus	NULL
CML	NULL
myeloid	NULL
cells	NULL
.	NULL

Alpha-interferon	NULL
appears	NULL
to	NULL
oppose	NULL
this	NULL
effect	NULL
of	NULL
CML	NULL
cytoplasmic	NULL
proteins	NULL
on	NULL
the	NULL
electrophoretic	NULL
mobility	NULL
of	NULL
nuclear	NULL
protein-DNA	NULL
complexes	NULL
in	NULL
cells	NULL
of	NULL
CML	NULL
patients	NULL
clinically	NULL
sensitive	NULL
to	NULL
IFN-a	NULL
.	NULL

The	NULL
sensitivity	NULL
of	NULL
cells	NULL
to	NULL
the	NULL
IFN-induced	NULL
changes	NULL
of	NULL
the	NULL
electrophoretic	NULL
mobility	NULL
of	NULL
nuclear	NULL
protein-DNA	NULL
complexes	NULL
was	NULL
observed	NULL
in	NULL
10	NULL
of	NULL
10	NULL
IFN-a	NULL
«	NULL
hematologic	NULL
responders	NULL
tested	NULL
,	NULL
in	NULL
11	NULL
of	NULL
12	NULL
partial	NULL
cytogenetic	NULL
responders	NULL
tested	NULL
,	NULL
and	NULL
in	NULL
seven	NULL
of	NULL
seven	NULL
of	NULL
the	NULL
complete	NULL
cytogenetic	NULL
responders	NULL
tested	NULL
.	NULL

The	NULL
complexes	NULL
formed	NULL
by	NULL
the	NULL
interferon-inducible	NULL
transcriptional	NULL
enhancer	NULL
and	NULL
the	NULL
nuclear	NULL
proteins	NULL
of	NULL
only	NULL
one	NULL
of	NULL
the	NULL
13	NULL
IFN-a-resistant	NULL
CML	NULL
patients	NULL
tested	NULL
exhibited	NULL
changes	NULL
in	NULL
electrophoretic	NULL
mobility	NULL
following	NULL
IFN	NULL
.	NULL

This	NULL
difference	NULL
between	NULL
the	NULL
sensitivity	NULL
to	NULL
the	NULL
IFN-a-induced	NULL
effect	NULL
on	NULL
nuclear	NULL
protein-DNA	NULL
complexes	NULL
in	NULL
clinically	NULL
sensitive	NULL
(	NULL
28	NULL
of	NULL
29	NULL
)	NULL
and	NULL
resistant	NULL
(	NULL
one	NULL
of	NULL
13	NULL
)	NULL
patients	NULL
was	NULL
statistically	NULL
significant	NULL
(	NULL
P	NULL
<	NULL
.01	NULL
)	NULL
(	NULL
Table	NULL
2	NULL
)	NULL
.	NULL

A	NULL
correlation	NULL
between	NULL
in	NULL
vitro	NULL
sensitivity	NULL
to	NULL
the	NULL
antiproliferative	NULL
effect	NULL
of	NULL
IFN	NULL
and	NULL
the	NULL
sensitivity	NULL
to	NULL
the	NULL
IFN-	NULL
«	NULL
-induced	NULL
changes	NULL
in	NULL
the	NULL
binding	NULL
of	NULL
nuclear	NULL
proteins	NULL
has	NULL
also	NULL
recently	NULL
been	NULL
reported	NULL
in	NULL
IFN-sensitive	NULL
and	NULL
-resistant	NULL
B	NULL
cell	NULL
lines	NULL
.	NULL

'*	NULL
Our	NULL
data	NULL
suggest	NULL
that	NULL
the	NULL
pathway	NULL
through	NULL
which	NULL
IFN	NULL
induces	NULL
changes	NULL
in	NULL
the	NULL
electrophoretic	NULL
mobility	NULL
of	NULL
nuclear	NULL
protein-DNA	NULL
complexes	NULL
may	NULL
be	NULL
playing	NULL
a	NULL
role	NULL
in	NULL
the	NULL
From	NULL
www	NULL
.	NULL

bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

1128	NULL
HOWARD	NULL
ET	NULL
AL	NULL
1	NULL
:	NULL
'	NULL
2	NULL
``	NULL
s	NULL
~	NULL
#	NULL
«	NULL
*	NULL
to	NULL
«	NULL
-	NULL
I	NULL
<	NULL
-	NULL
A	NULL
*	NULL
®	NULL
s	NULL
<	NULL
a	NULL
B	NULL
1	NULL
2	NULL
§	NULL
a	NULL
C	NULL
Fig	NULL
6	NULL
.	NULL

Chronic	NULL
myelogenous	NULL
leukemia	NULL
cytoplasmic	NULL
protein	NULL
changes	NULL
the	NULL
mobility	NULL
of	NULL
nuclear	NULL
protein	NULL
complexes	NULL
with	NULL
IFN-inducible	NULL
transcriptional	NULL
enhancers	NULL
.	NULL

(	NULL
a	NULL
)	NULL
A	NULL
cytoplasmic	NULL
protein	NULL
lysate	NULL
from	NULL
an	NULL
IFN-sensitive	NULL
CML	NULL
patient	NULL
was	NULL
added	NULL
in	NULL
a	NULL
1:1	NULL
ratio	NULL
to	NULL
Daudi	NULL
cell	NULL
line	NULL
nuclear	NULL
proteins	NULL
.	NULL

The	NULL
Daudi	NULL
cell	NULL
nuclear	NULL
proteins	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
form	NULL
a	NULL
low-mobility	NULL
complex	NULL
with	NULL
the	NULL
2,5-O0AS	NULL
transcriptional	NULL
enhancer	NULL
,	NULL
which	NULL
has	NULL
the	NULL
same	NULL
electrophoretic	NULL
mobility	NULL
as	NULL
that	NULL
formed	NULL
between	NULL
the	NULL
2,5-O0AS	NULL
transcriptional	NULL
enhancer	NULL
and	NULL
the	NULL
nuclear	NULL
proteins	NULL
of	NULL
normal	NULL
lymphoid	NULL
cells	NULL
.	NULL

Lanes	NULL
1	NULL
and	NULL
4	NULL
:	NULL
the	NULL
mobility	NULL
of	NULL
complexes	NULL
formed	NULL
between	NULL
the	NULL
cytoplasmic	NULL
lysate	NULL
of	NULL
CML	NULL
cells	NULL
and	NULL
the	NULL
2,5-0AS	NULL
oligonucleotide	NULL
(	NULL
complexes	NULL
only	NULL
faintly	NULL
visible	NULL
at	NULL
this	NULL
protein	NULL
concentration	NULL
:	NULL
5	NULL
ug/reaction	NULL
)	NULL
.	NULL

Lane	NULL
2	NULL
:	NULL
The	NULL
mobility	NULL
of	NULL
complexes	NULL
formed	NULL
between	NULL
the	NULL
2,5-O0AS	NULL
oligonucleotide	NULL
with	NULL
Daudi	NULL
cell	NULL
nuclear	NULL
proteins	NULL
after	NULL
incubation	NULL
with	NULL
a	NULL
cytoplasmic	NULL
lysate	NULL
of	NULL
CML	NULL
cells	NULL
for	NULL
1	NULL
hour	NULL
at	NULL
22°C	NULL
(	NULL
this	NULL
lane	NULL
shows	NULL
almost	NULL
complete	NULL
conversion	NULL
of	NULL
the	NULL
low-mobility	NULL
complex	NULL
to	NULL
the	NULL
high-mobility	NULL
complex	NULL
}	NULL
.	NULL

Lane	NULL
3	NULL
:	NULL
the	NULL
mobility	NULL
of	NULL
complexes	NULL
between	NULL
the	NULL
2,5-O0AS	NULL
oligonucleotide	NULL
and	NULL
Daudi	NULL
cell	NULL
nuclear	NULL
proteins	NULL
before	NULL
exposure	NULL
to	NULL
the	NULL
CML	NULL
cytoplasmic	NULL
proteins	NULL
.	NULL

Lane	NULL
5	NULL
:	NULL
the	NULL
mobility	NULL
of	NULL
complexes	NULL
between	NULL
the	NULL
2,5-O0AS	NULL
oligonucleotide	NULL
and	NULL
Daudi	NULL
cell	NULL
nuclear	NULL
proteins	NULL
after	NULL
incubstion	NULL
for	NULL
an	NULL
hour	NULL
with	NULL
a	NULL
cytoplasmic	NULL
protein	NULL
lysate	NULL
extracted	NULL
from	NULL
CML	NULL
cells	NULL
exposed	NULL
to	NULL
1,000	NULL
U/ml	NULL
.	NULL

of	NULL
IFN-a	NULL
.	NULL

The	NULL
cytoplasmic	NULL
protein	NULL
of	NULL
CML	NULL
cells	NULL
alters	NULL
the	NULL
electrophoretic	NULL
mobility	NULL
of	NULL
the	NULL
nuclear	NULL
protein-DNA	NULL
low-mobility	NULL
complex	NULL
(	NULL
band	NULL
A	NULL
)	NULL
,	NULL
as	NULL
shown	NULL
in	NULL
lane	NULL
2	NULL
.	NULL

Interferon	NULL
reduces	NULL
the	NULL
effect	NULL
of	NULL
the	NULL
CML	NULL
cytoplasmic	NULL
protein	NULL
on	NULL
electrophoretic	NULL
mobility	NULL
of	NULL
band	NULL
A	NULL
,	NULL
as	NULL
shown	NULL
in	NULL
lane	NULL
5	NULL
.	NULL

Most	NULL
of	NULL
the	NULL
unbound	NULL
probe	NULL
had	NULL
been	NULL
run	NULL
off	NULL
of	NULL
this	NULL
gel	NULL
.	NULL

(	NULL
b	NULL
)	NULL
ThwwwdtﬁodeMMMMFN-vm	NULL
“	NULL
Mmowhl	NULL
‘	NULL
l1nﬂotonoduvprm	NULL
purified	NULL
from	NULL
the	NULL
Daudi	NULL
cell	NULL
line	NULL
.	NULL

Lanes	NULL
1	NULL
and	NULL
2	NULL
depict	NULL
the	NULL
formed	NULL
b	NULL
the	NULL
2,5-O0AS	NULL
oligonucleotide	NULL
and	NULL
the	NULL
Daudi	NULL
nuclear	NULL
wmwmotmtiwmu¢mznmowonmmmwmammamwdm	NULL
IFN-resistant	NULL
CML	NULL
patient	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
.	NULL

The	NULL
cytoplasmic	NULL
proteins	NULL
were	NULL
added	NULL
in	NULL
the	NULL
pr	NULL
of	NULL
pr	NULL
inhibitors	NULL
.	NULL

The	NULL
addition	NULL
of	NULL
the	NULL
cytoplasmic	NULL
proteins	NULL
resulted	NULL
in	NULL
almost	NULL
a	NULL
complete	NULL
conversion	NULL
of	NULL
the	NULL
low-mobility	NULL
complex	NULL
to	NULL
the	NULL
high-mobility	NULL
complex	NULL
.	NULL

in	NULL
lane	NULL
3	NULL
,	NULL
the	NULL
cells	NULL
of	NULL
the	NULL
IFN-resistant	NULL
CML	NULL
patient	NULL
were	NULL
exposed	NULL
to	NULL
IFN	NULL
before	NULL
isolation	NULL
of	NULL
the	NULL
cytoplasmic	NULL
proteins	NULL
of	NULL
the	NULL
CML	NULL
cells	NULL
.	NULL

There	NULL
is	NULL
no	NULL
effect	NULL
of	NULL
IFN	NULL
on	NULL
the	NULL
lysate-induced	NULL
change	NULL
in	NULL
electrophoretic	NULL
mobility	NULL
of	NULL
the	NULL
low-mobility	NULL
nuclear	NULL
protein-DNA	NULL
complex	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
.	NULL

The	NULL
unbound	NULL
probe	NULL
had	NULL
been	NULL
run	NULL
off	NULL
of	NULL
this	NULL
gel	NULL
.	NULL

(	NULL
c	NULL
)	NULL
The	NULL
cytoplasmic	NULL
proteins	NULL
of	NULL
the	NULL
peripheral	NULL
blood	NULL
cells	NULL
of	NULL
a	NULL
normal	NULL
individual	NULL
were	NULL
added	NULL
in	NULL
a	NULL
1:1	NULL
ratio	NULL
to	NULL
the	NULL
nuclear	NULL
proteins	NULL
purified	NULL
from	NULL
the	NULL
Daudi	NULL
cell	NULL
line	NULL
.	NULL

The	NULL
mobility	NULL
of	NULL
complexes	NULL
between	NULL
the	NULL
2,5-O0AS	NULL
oligonucleotide	NULL
with	NULL
Daudi	NULL
nuclear	NULL
proteins	NULL
before	NULL
(	NULL
lane	NULL
1	NULL
}	NULL
and	NULL
after	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
addition	NULL
of	NULL
cytoplasmic	NULL
proteins	NULL
from	NULL
the	NULL
mature	NULL
marrow	NULL
cells	NULL
(	NULL
bands	NULL
and	NULL
neutrophils	NULL
)	NULL
of	NULL
a	NULL
normal	NULL
individual	NULL
.	NULL

In	NULL
lane	NULL
2	NULL
,	NULL
the	NULL
cytoplasmic	NULL
proteins	NULL
of	NULL
the	NULL
immature	NULL
marrow	NULL
myeloid	NULL
cells	NULL
of	NULL
a	NULL
normal	NULL
individual	NULL
(	NULL
blasts	NULL
and	NULL
promyelocytes	NULL
)	NULL
were	NULL
added	NULL
to	NULL
the	NULL
Daudi	NULL
nuclear	NULL
proteins	NULL
before	NULL
incubation	NULL
with	NULL
the	NULL
2,5-OAS	NULL
transcriptional	NULL
enhancer	NULL
.	NULL

The	NULL
cytoplasmic	NULL
proteins	NULL
were	NULL
added	NULL
for	NULL
1	NULL
hour	NULL
at	NULL
22°C	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
protease	NULL
inhibitors	NULL
.	NULL

These	NULL
complexes	NULL
were	NULL
electrophoresed	NULL
in	NULL
a	NULL
mobility-shift	NULL
gel	NULL
for	NULL
12	NULL
hours	NULL
at	NULL
5	NULL
V/cm	NULL
.	NULL

The	NULL
low-mobility	NULL
complex	NULL
from	NULL
Daudi	NULL
is	NULL
labeled	NULL
``	NULL
A	NULL
.	NULL
``	NULL

''	NULL
The	NULL
new	NULL
band	NULL
generated	NULL
in	NULL
Daudi	NULL
by	NULL
the	NULL
CML	NULL
protein	NULL
cellular	NULL
extract	NULL
is	NULL
labeled	NULL
``	NULL
B	NULL
.	NULL
``	NULL

''	NULL
There	NULL
is	NULL
only	NULL
a	NULL
minor	NULL
effect	NULL
of	NULL
the	NULL
cytoplasmic	NULL
protein	NULL
of	NULL
normal	NULL
mature	NULL
peripheral	NULL
blood	NULL
mysloid	NULL
cells	NULL
on	NULL
the	NULL
electrophoretic	NULL
mobility	NULL
of	NULL
the	NULL
Daudi	NULL
nuclear	NULL
protein-DNA	NULL
complexes	NULL
.	NULL

The	NULL
area	NULL
at	NULL
the	NULL
bottom	NULL
of	NULL
each	NULL
lane	NULL
shows	NULL
the	NULL
unbound	NULL
probe	NULL
.	NULL

From	NULL
www	NULL
.	NULL

bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

INTERFERON	NULL
AND	NULL
NUCLEAR	NULL
PROTEINS	NULL
IN	NULL
CML	NULL
Lt	NULL
;	NULL
-s	NULL
it	NULL
}	NULL
Fig	NULL
7	NULL
.	NULL

Effect	NULL
of	NULL
acid	NULL
phosphatase	NULL
on	NULL
nuclear	NULL
protein	NULL
complexes	NULL
.	NULL

Nuclear	NULL
protein-DNA	NULL
complexes	NULL
were	NULL
incubated	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
potato	NULL
white	NULL
acid	NULL
phosphatase	NULL
(	NULL
4	NULL
U/20	NULL
ul/10	NULL
ug	NULL
nuclear	NULL
protein	NULL
)	NULL
for	NULL
10	NULL
minutes	NULL
at	NULL
22°C	NULL
.	NULL

Lane	NULL
1	NULL
:	NULL
mobility	NULL
of	NULL
complex	NULL
between	NULL
the	NULL
2.5-O0AS	NULL
interferon-inducible	NULL
transcriptional	NULL
enhancer	NULL
and	NULL
nuclear	NULL
proteins	NULL
from	NULL
the	NULL
Daudi	NULL
cell	NULL
line	NULL
before	NULL
exposure	NULL
to	NULL
phosphatase	NULL
.	NULL

Lanes	NULL
2	NULL
and	NULL
3	NULL
:	NULL
mobility	NULL
of	NULL
the	NULL
same	NULL
complex	NULL
after	NULL
exposure	NULL
to	NULL
acid	NULL
phosphatase	NULL
.	NULL

Lane	NULL
4	NULL
:	NULL
electrophoretic	NULL
mobility	NULL
of	NULL
the	NULL
complex	NULL
between	NULL
the	NULL
2,5-O0AS	NULL
enhancer	NULL
and	NULL
nuclear	NULL
proteins	NULL
of	NULL
the	NULL
CML	NULL
cell	NULL
line	NULL
EM-2	NULL
.	NULL

The	NULL
electrophoretic	NULL
mobility	NULL
of	NULL
complexes	NULL
formed	NULL
between	NULL
the	NULL
Daudi	NULL
cell	NULL
nuclear	NULL
proteins	NULL
and	NULL
the	NULL
2,5-OAS	NULL
transcriptional	NULL
enhancer	NULL
is	NULL
the	NULL
same	NULL
as	NULL
the	NULL
mobility	NULL
of	NULL
complexes	NULL
formed	NULL
between	NULL
the	NULL
2,5-0AS	NULL
enhancer	NULL
and	NULL
the	NULL
nuclear	NULL
proteins	NULL
of	NULL
normal	NULL
lymphoid	NULL
cells	NULL
.	NULL

Band	NULL
A	NULL
is	NULL
the	NULL
low-mobility	NULL
complex	NULL
and	NULL
band	NULL
B	NULL
is	NULL
the	NULL
high-mobility	NULL
complex	NULL
.	NULL

The	NULL
gel	NULL
was	NULL
run	NULL
for	NULL
12	NULL
hours	NULL
at	NULL
5	NULL
V/cm	NULL
.	NULL

The	NULL
area	NULL
at	NULL
the	NULL
bottom	NULL
of	NULL
each	NULL
lane	NULL
contains	NULL
the	NULL
unbound	NULL
probe	NULL
.	NULL

clinical	NULL
effects	NULL
of	NULL
IFN	NULL
in	NULL
CML	NULL
.	NULL

It	NULL
is	NULL
not	NULL
yet	NULL
clear	NULL
that	NULL
the	NULL
transcriptional	NULL
activation	NULL
of	NULL
gene	NULL
transcription	NULL
is	NULL
important	NULL
to	NULL
the	NULL
clinical	NULL
antiproliferative	NULL
effect	NULL
of	NULL
IFN-a	NULL
in	NULL
CML	NULL
or	NULL
whether	NULL
the	NULL
antiproliferative	NULL
effect	NULL
is	NULL
mediated	NULL
through	NULL
a	NULL
1129	NULL
direct	NULL
cytoplasmic	NULL
pathway	NULL
.	NULL

The	NULL
IFN-induced	NULL
change	NULL
in	NULL
electrophoretic	NULL
mobility	NULL
of	NULL
the	NULL
2,5-0AS	NULL
transcriptional	NULL
enhancer	NULL
nuclear	NULL
protein	NULL
complex	NULL
may	NULL
be	NULL
an	NULL
indicator	NULL
of	NULL
an	NULL
event	NULL
predictive	NULL
of	NULL
clinical	NULL
sensitivity	NULL
or	NULL
resistance	NULL
without	NULL
being	NULL
linked	NULL
to	NULL
transcriptional	NULL
activation	NULL
of	NULL
IFN-inducible	NULL
genes	NULL
.	NULL

The	NULL
in	NULL
vitro	NULL
effect	NULL
of	NULL
IFN-a	NULL
on	NULL
nuclear	NULL
proteins	NULL
from	NULL
CML	NULL
patients	NULL
occurs	NULL
within	NULL
1	NULL
hour	NULL
after	NULL
exposure	NULL
of	NULL
the	NULL
cells	NULL
to	NULL
IFN	NULL
and	NULL
is	NULL
not	NULL
associated	NULL
with	NULL
changes	NULL
in	NULL
the	NULL
percentages	NULL
of	NULL
lymphoid	NULL
or	NULL
myeloid	NULL
cells	NULL
in	NULL
the	NULL
peripheral	NULL
blood	NULL
of	NULL
CML	NULL
patients	NULL
.	NULL

Studies	NULL
by	NULL
other	NULL
investigators	NULL
have	NULL
shown	NULL
that	NULL
transcriptional	NULL
activation	NULL
by	NULL
IFN-a	NULL
starts	NULL
to	NULL
take	NULL
place	NULL
within	NULL
5	NULL
minutes	NULL
and	NULL
peaks	NULL
within	NULL
1	NULL
hour	NULL
of	NULL
its	NULL
binding	NULL
to	NULL
the	NULL
plasma	NULL
membrane	NULL
IFN	NULL
receptor	NULL
.	NULL

:	NULL
:	NULL
Furthermore	NULL
,	NULL
the	NULL
IFN-induced	NULL
changes	NULL
in	NULL
the	NULL
nuclear	NULL
proteins	NULL
of	NULL
IFN-inducible	NULL
genes	NULL
started	NULL
to	NULL
occur	NULL
within	NULL
the	NULL
first	NULL
4	NULL
minutes	NULL
in	NULL
the	NULL
studies	NULL
of	NULL
others	NULL
.	NULL

:	NULL
This	NULL
early	NULL
effect	NULL
of	NULL
IFN-a	NULL
,	NULL
which	NULL
is	NULL
insensitive	NULL
to	NULL
cycloheximide	NULL
inhibition	NULL
in	NULL
our	NULL
studies	NULL
and	NULL
in	NULL
those	NULL
of	NULL
others	NULL
,	NULL
:	NULL
occurs	NULL
at	NULL
a	NULL
time	NULL
that	NULL
is	NULL
synchronous	NULL
with	NULL
the	NULL
activation	NULL
of	NULL
gene	NULL
expression	NULL
.	NULL

:	NULL
:	NULL
s	NULL
Our	NULL
studies	NULL
suggest	NULL
that	NULL
the	NULL
IFN-a-induced	NULL
changes	NULL
in	NULL
the	NULL
electrophoretic	NULL
mobility	NULL
of	NULL
the	NULL
nuclear	NULL
protein	NULL
complexes	NULL
is	NULL
due	NULL
to	NULL
a	NULL
posttranslational	NULL
modification	NULL
of	NULL
nuclear	NULL
proteins	NULL
,	NULL
since	NULL
this	NULL
is	NULL
not	NULL
inhibitable	NULL
by	NULL
cycloheximide	NULL
.	NULL

The	NULL
differences	NULL
in	NULL
mobility	NULL
of	NULL
the	NULL
complexes	NULL
between	NULL
nuclear	NULL
proteins	NULL
and	NULL
IFN-inducible	NULL
transcriptional	NULL
enhancers	NULL
could	NULL
be	NULL
due	NULL
to	NULL
the	NULL
posttranslational	NULL
modification	NULL
of	NULL
a	NULL
single	NULL
protein	NULL
or	NULL
to	NULL
binding	NULL
of	NULL
different	NULL
nuclear	NULL
proteins	NULL
to	NULL
the	NULL
IFN-inducible	NULL
transcriptional	NULL
enhancer	NULL
.	NULL

The	NULL
nuclear	NULL
protein	NULL
binding	NULL
assay	NULL
described	NULL
in	NULL
this	NULL
report	NULL
may	NULL
be	NULL
useful	NULL
in	NULL
predicting	NULL
the	NULL
responsiveness	NULL
of	NULL
CML	NULL
patients	NULL
to	NULL
IFN-a	NULL
therapy	NULL
.	NULL

We	NULL
are	NULL
conducting	NULL
a	NULL
prospective	NULL
evaluation	NULL
of	NULL
this	NULL
assay	NULL
as	NULL
a	NULL
predictor	NULL
of	NULL
de	NULL
novo	NULL
sensitivity	NULL
or	NULL
resistance	NULL
to	NULL
IFN-	NULL
«	NULL
.	NULL

Further	NULL
studies	NULL
will	NULL
focus	NULL
on	NULL
the	NULL
characterization	NULL
of	NULL
the	NULL
structure	NULL
of	NULL
these	NULL
nuclear	NULL
proteins	NULL
and	NULL
their	NULL
posttranslational	NULL
modifications	NULL
,	NULL
which	NULL
occur	NULL
in	NULL
both	NULL
normal	NULL
individuals	NULL
and	NULL
CML	NULL
patients	NULL
after	NULL
exposure	NULL
to	NULL
IFN	NULL
.	NULL

ACKNOWLEDGMENT	NULL
The	NULL
authors	NULL
acknowledge	NULL
the	NULL
technical	NULL
support	NULL
of	NULL
Robin	NULL
Luttrell	NULL
,	NULL
Debra	NULL
Elierson	NULL
,	NULL
Michele	NULL
Herrick	NULL
,	NULL
and	NULL
April	NULL
Durett	NULL
;	NULL
typing	NULL
by	NULL
Rosemarie	NULL
Lauzon	NULL
;	NULL
and	NULL
clinical	NULL
data	NULL
collection	NULL
by	NULL
Deborah	NULL
Geissler	NULL
,	NULL
Allison	NULL
Hendrickson	NULL
,	NULL
and	NULL
Lurie	NULL
Foster	NULL
.	NULL

We	NULL
thank	NULL
Michael	NULL
Shephard	NULL
of	NULL
Genentech	NULL
for	NULL
a	NULL
gift	NULL
of	NULL
IFN-	NULL
«	NULL
and	NULL
Stephen	NULL
Smith	NULL
of	NULL
the	NULL
University	NULL
of	NULL
Chicago	NULL
for	NULL
a	NULL
gift	NULL
of	NULL
the	NULL
SP-5	NULL
cell	NULL
line	NULL
.	NULL

We	NULL
also	NULL
thank	NULL
the	NULL
staff	NULL
of	NULL
the	NULL
Division	NULL
of	NULL
Laboratory	NULL
Medicine	NULL
,	NULL
Cytogenetics	NULL
Laboratory	NULL
,	NULL
of	NULL
the	NULL
University	NULL
of	NULL
Texas	NULL
M.D	NULL
.	NULL

Anderson	NULL
Cancer	NULL
Center	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Talpaz	NULL
M	NULL
,	NULL
Kantarjian	NULL
HM	NULL
,	NULL
McCredie	NULL
K	NULL
,	NULL
Trujillo	NULL
JM	NULL
,	NULL
Keating	NULL
MJ	NULL
,	NULL
Gutterman	NULL
JU	NULL
:	NULL
Hematologic	NULL
remission	NULL
and	NULL
cytogenetic	NULL
improvement	NULL
induced	NULL
by	NULL
recombinant	NULL
human	NULL
interferon	NULL
alpha	NULL
,	NULL
in	NULL
chronic	NULL
myelogenous	NULL
leukemia	NULL
.	NULL

N	NULL
Eng	NULL
!	NULL

J	NULL
Med	NULL
314:1065	NULL
,	NULL
1986	NULL
2	NULL
.	NULL

Benech	NULL
P	NULL
,	NULL
Vigneron	NULL
M	NULL
,	NULL
Peretz	NULL
D	NULL
,	NULL
Revel	NULL
M	NULL
,	NULL
Chebath	NULL
J	NULL
:	NULL
Interferon-responsive	NULL
regulatory	NULL
elements	NULL
in	NULL
the	NULL
promoter	NULL
of	NULL
the	NULL
human	NULL
(	NULL
A	NULL
)	NULL
synthetase	NULL
gene	NULL
.	NULL

Mol	NULL
Cell	NULL
Biol	NULL
7:4498	NULL
,	NULL
1987	NULL
3	NULL
.	NULL

Friedman	NULL
RL	NULL
,	NULL
Stark	NULL
GR	NULL
:	NULL
Alpha-interferon-induced	NULL
transcription	NULL
of	NULL
HLA	NULL
and	NULL
metallothioncin	NULL
genes	NULL
containing	NULL
homologous	NULL
upstream	NULL
sequences	NULL
.	NULL

Nature	NULL
314:637	NULL
,	NULL
1985	NULL
4	NULL
.	NULL

Gussow	NULL
D	NULL
,	NULL
Rein	NULL
R	NULL
,	NULL
Ginjaar	NULL
I	NULL
,	NULL
Hochstenbach	NULL
F	NULL
,	NULL
Seemann	NULL
G	NULL
,	NULL
Kottman	NULL
A	NULL
,	NULL
Ploegh	NULL
HL	NULL
:	NULL
The	NULL
human	NULL
beta-	NULL
,	NULL
microglobulin	NULL
gene	NULL
.	NULL

Primary	NULL
structure	NULL
and	NULL
definition	NULL
of	NULL
the	NULL
transcriptional	NULL
unit	NULL
.	NULL

J	NULL
Immunol	NULL
139:3132	NULL
,	NULL
1987	NULL
From	NULL
www	NULL
.	NULL

bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

1130	NULL
5	NULL
.	NULL

Porter	NULL
ACG	NULL
,	NULL
Chernajovsky	NULL
Y	NULL
,	NULL
Dale	NULL
TC	NULL
,	NULL
Gilbert	NULL
CS	NULL
,	NULL
Stark	NULL
GR	NULL
,	NULL
Kerr	NULL
IM	NULL
:	NULL
Interferon	NULL
response	NULL
element	NULL
of	NULL
the	NULL
human	NULL
gene	NULL
6-16	NULL
.	NULL

EMBO	NULL
J	NULL
7:85	NULL
,	NULL
1988	NULL
6	NULL
.	NULL

Reich	NULL
N	NULL
,	NULL
Evans	NULL
B	NULL
,	NULL
Levy	NULL
D	NULL
,	NULL
Fahey	NULL
D	NULL
,	NULL
Knight	NULL
E	NULL
,	NULL
Darnell	NULL
JE	NULL
:	NULL
Interferon-induced	NULL
transcription	NULL
of	NULL
a	NULL
gene	NULL
encoding	NULL
a	NULL
15-kDa	NULL
protein	NULL
depends	NULL
on	NULL
an	NULL
upstream	NULL
enhancer	NULL
element	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
84:6394	NULL
,	NULL
1987	NULL
7	NULL
.	NULL

Reid	NULL
LE	NULL
,	NULL
Brasnett	NULL
AH	NULL
,	NULL
Gilbert	NULL
CS	NULL
,	NULL
Porter	NULL
ACG	NULL
,	NULL
Gewert	NULL
DR	NULL
,	NULL
Stark	NULL
GR	NULL
,	NULL
Kerr	NULL
IM	NULL
:	NULL
A	NULL
single	NULL
DNA	NULL
response	NULL
element	NULL
can	NULL
confer	NULL
inducibility	NULL
by	NULL
both	NULL
alpha	NULL
and	NULL
gamma	NULL
interferons	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
86:840	NULL
,	NULL
1989	NULL
8	NULL
.	NULL

Rutherford	NULL
MN	NULL
,	NULL
Hannigan	NULL
GE	NULL
,	NULL
Williams	NULL
BRG	NULL
:	NULL
Interferon-induced	NULL
binding	NULL
of	NULL
nuclear	NULL
factors	NULL
to	NULL
promoter	NULL
elements	NULL
of	NULL
the	NULL
2-5A	NULL
synthetase	NULL
gene	NULL
.	NULL

EMBO	NULL
J	NULL
7:751	NULL
,	NULL
1988	NULL
9	NULL
.	NULL

Sugita	NULL
K	NULL
,	NULL
Miyazaki	NULL
JI	NULL
,	NULL
Appella	NULL
E	NULL
,	NULL
Ozato	NULL
K	NULL
:	NULL
Interferons	NULL
increase	NULL
transcription	NULL
of	NULL
a	NULL
major	NULL
histocompatibility	NULL
class	NULL
I	NULL
gene	NULL
via	NULL
a	NULL
5	NULL
'	NULL
interferon	NULL
consensus	NULL
sequence	NULL
.	NULL

Mol	NULL
Cell	NULL
Biol	NULL
7:2625	NULL
,	NULL
1987	NULL
10	NULL
.	NULL

Miskimens	NULL
WK	NULL
,	NULL
Roberts	NULL
MP	NULL
,	NULL
McClelland	NULL
A	NULL
,	NULL
Ruddle	NULL
FH	NULL
:	NULL
Use	NULL
of	NULL
a	NULL
protein-blotting	NULL
procedure	NULL
and	NULL
a	NULL
specific	NULL
DNA	NULL
probe	NULL
to	NULL
identify	NULL
nuclear	NULL
proteins	NULL
that	NULL
recognize	NULL
the	NULL
promoter	NULL
region	NULL
of	NULL
the	NULL
transferrin	NULL
receptor	NULL
gene	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
82:6741	NULL
,	NULL
1985	NULL
11	NULL
.	NULL

Dignam	NULL
JD	NULL
,	NULL
Lebovitz	NULL
RM	NULL
,	NULL
Roeder	NULL
RG	NULL
:	NULL
Accurate	NULL
transcrip-	NULL
HOWARD	NULL
ET	NULL
AL	NULL
tion	NULL
initiation	NULL
by	NULL
RNA	NULL
polymerase	NULL
II	NULL
in	NULL
a	NULL
soluble	NULL
extract	NULL
from	NULL
isolated	NULL
mammalian	NULL
nuclei	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
11:1475	NULL
,	NULL
1983	NULL
12	NULL
.	NULL

Treisman	NULL
R	NULL
:	NULL
Identification	NULL
of	NULL
a	NULL
protein-binding	NULL
site	NULL
that	NULL
mediates	NULL
transcriptional	NULL
response	NULL
of	NULL
the	NULL
c-fos	NULL
gene	NULL
to	NULL
serum	NULL
factors	NULL
.	NULL

Cell	NULL
46:567	NULL
,	NULL
1986	NULL
13	NULL
.	NULL

Maxam	NULL
AM	NULL
,	NULL
Gilbert	NULL
W	NULL
:	NULL
Sequencing	NULL
end-labeled	NULL
DNA	NULL
with	NULL
base-specific	NULL
chemical	NULL
cleavages	NULL
.	NULL

Methods	NULL
Enzymol	NULL
65:499	NULL
,	NULL
1980	NULL
14	NULL
.	NULL

Kamar	NULL
R	NULL
,	NULL
Mendelsohn	NULL
J	NULL
:	NULL
Role	NULL
of	NULL
2	NULL
,	NULL
S5-oligoadenylate	NULL
synthetase	NULL
in	NULL
gamma-interferon	NULL
mediated	NULL
growth	NULL
inhibition	NULL
of	NULL
A431	NULL
cells	NULL
.	NULL

Cancer	NULL
Res	NULL
49:5180	NULL
,	NULL
1989	NULL
15	NULL
.	NULL

O'Neal	NULL
SG	NULL
,	NULL
Rhoads	NULL
DB	NULL
,	NULL
Rocker	NULL
E	NULL
:	NULL
Vanadate	NULL
inhibition	NULL
of	NULL
sarcoplasmic	NULL
reticulin	NULL
Ca*+*	NULL
ATPase	NULL
and	NULL
other	NULL
ATPases	NULL
.	NULL

Biochem	NULL
Biophys	NULL
Res	NULL
Commun	NULL
89:845	NULL
,	NULL
1979	NULL
16	NULL
.	NULL

Kessler	NULL
DS	NULL
,	NULL
Pine	NULL
R	NULL
,	NULL
Pfeffer	NULL
LM	NULL
,	NULL
Levy	NULL
DE	NULL
,	NULL
Darnell	NULL
JE	NULL
:	NULL
Cells	NULL
resistant	NULL
to	NULL
interferon	NULL
are	NULL
defective	NULL
in	NULL
activation	NULL
of	NULL
a	NULL
promoter-binding	NULL
factor	NULL
.	NULL

EMBO	NULL
J	NULL
7:3779	NULL
,	NULL
1988	NULL
17	NULL
.	NULL

Friedman	NULL
RL	NULL
,	NULL
Manly	NULL
SP	NULL
,	NULL
McMahon	NULL
M	NULL
,	NULL
Kerr	NULL
IM	NULL
,	NULL
Stark	NULL
GR	NULL
:	NULL
Transcriptional	NULL
and	NULL
post-transcriptional	NULL
regulation	NULL
of	NULL
the	NULL
interferon-induced	NULL
gene	NULL
expression	NULL
in	NULL
human	NULL
cells	NULL
.	NULL

Cell	NULL
38:745	NULL
,	NULL
1984	NULL
18	NULL
.	NULL

Hannigan	NULL
G	NULL
,	NULL
Williams	NULL
BRG	NULL
:	NULL
Transcriptional	NULL
regulation	NULL
of	NULL
interferon-responsive	NULL
genes	NULL
is	NULL
closely	NULL
linked	NULL
to	NULL
interferon	NULL
receptor	NULL
occupancy	NULL
.	NULL

EMBO	NULL
J	NULL
5:1607	NULL
,	NULL
1986	NULL
From	NULL
www	NULL
.	NULL

bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

®	NULL
blOOd	NULL
1990	NULL
76	NULL
:	NULL
1117-1130	NULL
Interferon	NULL
affects	NULL
nuclear	NULL
proteins	NULL
in	NULL
cells	NULL
of	NULL
clinically	NULL
sensitive	NULL
chronic	NULL
myelogenous	NULL
leukemia	NULL
patients	NULL
4	NULL
,	NULL
8	NULL
%	NULL
o	NULL
p	NULL
'	NULL
ﬁ	NULL
'	NULL
f	NULL
)	NULL
..	NULL
os	NULL
2101	NULL
%	NULL
N	NULL
@	NULL
0	NULL
OM	NULL
Howard	NULL
,	NULL
M	NULL
Talpaz	NULL
,	NULL
H	NULL
Kantarjian	NULL
,	NULL
D	NULL
Seong	NULL
,	NULL
A	NULL
Wedrychowski	NULL
,	NULL
N	NULL
Paslidis	NULL
,	NULL
J	NULL
Hester	NULL
,	NULL
A	NULL
Cork	NULL
,	NULL
J	NULL
Turpin	NULL
and	NULL
G	NULL
Lopez-Berestein	NULL
Updated	NULL
information	NULL
and	NULL
services	NULL
can	NULL
be	NULL
found	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.bloodjournal.org/content/76/6/1117.full.html	NULL
Articles	NULL
on	NULL
similar	NULL
topics	NULL
can	NULL
be	NULL
found	NULL
in	NULL
the	NULL
following	NULL
Blood	NULL
collections	NULL
Information	NULL
about	NULL
reproducing	NULL
this	NULL
article	NULL
in	NULL
parts	NULL
or	NULL
in	NULL
its	NULL
entirety	NULL
may	NULL
be	NULL
found	NULL
online	NULL
at	NULL
:	NULL
requests	NULL
Information	NULL
about	NULL
ordering	NULL
reprints	NULL
may	NULL
be	NULL
found	NULL
online	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.bloodjournal.org/site/misc/rights.xhtml	NULL
#	NULL
reprints	NULL
Information	NULL
about	NULL
subscriptions	NULL
and	NULL
ASH	NULL
membership	NULL
may	NULL
be	NULL
found	NULL
online	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.bloodjournal.org/site/subscriptions/index.xhtml	NULL
Blood	NULL
(	NULL
print	NULL
ISSN	NULL
0006-4971	NULL
,	NULL
online	NULL
ISSN	NULL
1528-0020	NULL
)	NULL
,	NULL
is	NULL
published	NULL
weekly	NULL
by	NULL
the	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
,	NULL
2021	NULL
L	NULL
St	NULL
,	NULL
NW	NULL
,	NULL
Suite	NULL
900	NULL
,	NULL
Washington	NULL
DC	NULL
20036	NULL
.	NULL

Copyright	NULL
2011	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
;	NULL
all	NULL
rights	NULL
reserved	NULL
.	NULL

